Caractérisation du gène de l'enzyme de conversion de
l'angiotensine-2 dans le rein diabétique et implication dans le
développement de la néphropathie diabétique et de l'hypertension by Shi, Yixuan
Université de Montréal 
 
 
Caractérisation du gène de l'enzyme de conversion de 
l'angiotensine-2 dans le rein diabétique et implication dans le 
développement de la néphropathie diabétique et de l'hypertension 
 
 
 
Par 
Yixuan Shi 
 
 
Programme de sciences biomédicales 
Faculté de médecine 
 
 
 
 
Thèse présentée à la faculté des études supérieures 
en vue de l’obtention du grade de docteurès sciences (Ph.D.) 
en sciences biomédicales 
 
 
 
July 2014 
 
 
 
© Yixuan Shi 2014 
 
 ii 
Université de Montréal 
 
 
Caractérisation du gène de l'enzyme de conversion de 
l'angiotensine-2 dans le rein diabétique et implication dans le 
développement de la néphropathie diabétique et de l'hypertension 
 
 
 
Par 
Yixuan Shi 
 
 
a été évaluée par un jury composé des personnes suivantes : 
 
 
Dre Jolanta Gutkowska 
Présidente  rapporteuse 
 
Dr John S.D. Chan 
Directeur de recherche 
 
 
Dre Shao-Ling Zhang 
Codirectrice de recherche 
 
 
Dr Stéphan Troyanov 
Membre du jury 
 
Dr David Cherney 
Examinateur externe  
 iii 
 
Résumé 
De nombreuses études ont bien démontré que l’activation du système rénine-angiotensine 
(RAS) joue un rôle important dans le développement de l’hypertension et de la néphropathie 
diabétique (DN). La découverte de l’enzyme de conversion de l’angiotensine-2 (ACE2) et 
l’identification du récepteur MAS, spécifique pour l’angiotensine 1-7 (Ang 1-7), ont permis 
d’identifier deux nouveaux membres du RAS. L’axe ACE2/Ang 1-7/MAS contrebalance les 
effets de l’axe ACE/Ang II/AT1. Plusieurs évidences impliquent la contribution du RAS 
intrarénal dans la DN. Des études réalisées dans notre laboratoire avec des souris 
transgéniques surexprimant l’angiotensinogène de rat dans les cellules de leurs tubules 
proximaux rénaux (RPTCs) ont permis de démontrer l’importance du RAS intrarénal dans 
l’induction de l’hypertension et les dommages rénaux. Nous avons également observé que 
l’expression rénale de l’ACE2 et les niveaux urinaires d’ANG 1-7 sont plus faibles chez les 
souris Akita (diabète de type 1) et qu’un traitement avec des bloqueurs du RAS permet de 
normaliser l’expression de l’ACE2 et de prévenir le développement de l’hypertension dans le 
modèle des souris Akita. Dans un milieu diabétique, à la fois la glycémie et l’angiotensine II 
(Ang II) peuvent induire la génération des espèces réactives de l’oxygène (ROS), contribuant 
ainsi aux dommages rénaux. Afin d’explorer la relation entre les ROS, ACE2 et la DN, nous 
avons créé des souris Akita transgéniques surexprimant la catalase (Cat) dans les RPTCs, en 
croisant des souris Akita diabétique de type 1 à notre modèle de souris transgéniques 
surexprimant la Cat de rat dans les RPTCs. Dans une seconde étude, des souris Akita ont été 
traitées avec l’Ang 1-7 ou une combinaison d’Ang 1-7 et de son antagoniste, A779, afin 
 iv 
d’étudier la relation entre l’action de l’Ang 1-7, l’hypertension systolique (sHTN), le stress 
oxydatif, les dommages rénaux, ACE2 et l’expression du récepteur Mas. 
Nos résultats ont montré que la surexpression de Cat atténue le stress oxydatif rénal; prévient 
l’hypertension, améliore le taux de filtration glomérulaire, l’albuminurie, l’hypertrophie 
rénale, la fibrose tubulo-interstitielle et l’apoptose tubulaire; et supprime l’expression des 
gènes profibrotiques et proapoptotiques dans les RPTCs des souris Akita Cat-Tg lorsque 
comparées aux souris Akita. De plus, la surexpression de Cat dans les RPTC des souris Akita 
normalise l’expression rénale de l’ACE2 et les niveaux urinaires d’Ang 1-7. 
D’autre part, l’administration d’Ang 1-7  prévient l’hypertension systémique, normalise le 
ratio albumine/créatinine urinaire et atténue l’hyperfiltration glomérulaire des souris Akita, 
sans affecter la glycémie sanguine. De plus, le traitement avec l’Ang 1-7 atténue aussi le stress 
oxydatif et l’expression de la NADPH oxydase, Agt, ACE, TGF-β1 (transforming growth 
factor-β1) et collagène IV, tout en augmentant l’expression de l’ACE2 et du récepteur Mas 
dans les reins des souris Akita. Ces effets sont renversés par la co-admininstration d’A779. 
Ces résultats démontrent que la surexpression de Cat prévient l’hypertension et la progression 
de la néphropathie, en plus de mettre en lumière l’importance du stress oxydatif intrarénal et 
l’expression de l’ACE2 comme facteurs contribuant à l’hypertension et les dommages rénaux 
observés dans le diabète. En outre, nos données suggèrent que l’Ang 1-7 joue un rôle 
protecteur dans l’hypertension et les dommages aux RPTC dans le diabète, principalement en 
réduisant les voies de signalisations du stress oxydatif dans les reins et en normalisant 
l’expression de l’ACE2 et du récepteur Mas. Nos résultats indiquent aussi que l’Ang 1-7 
pourrait agir comme un agent thérapeutique potentiel dans le traitement de l’hypertension 
 v 
systémique et les dommages rénaux observés dans le diabète. En conséquence, l’Ang 1-7 est 
responsable du rôle protecteur de l’ACE2 dans l’hypertension et la DN. 
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Abstract 
It is well accepted that renin-angiotensin system (RAS) activation plays an important role in 
the development of hypertension and diabetic nephropathy (DN). With the discovery of 
angiotensin-converting enzyme-2 (ACE2) and recognition of MAS as the receptor of 
Angiotensin 1-7 (Ang 1-7), new players in RAS, ACE2/Ang 1-7/MAS axis, have been 
identified to counteract the effect of ACE/Ang II/ AT1 axis. Evidence implicates the intrarenal 
RAS’s contribution to DN. Previous studies from our laboratory using transgenic mice 
overexpressing rat Angiotensinogen (Agt) in their renal proximal tubular cells (RPTCs) have 
demonstrated the importance of the intrarenal RAS in renal damage and the induction of 
hypertension. We also recently observed that renal ACE2 expression and urinary Ang 1–7 
were lower in type 1 diabetic Akita mice and that treatment with RAS blockers normalized 
ACE2 expression and prevented hypertension development in these Akita mice. In the diabetic 
milieu, both glycemia and angiotensin II (Ang II) can induce reactive oxygen species (ROS) 
generation, which contributes to kidney injury. To explore the relationship among ROS, ACE2 
and DN, we created Akita transgenic mice overexpressing catalase (Cat) in RPTCs by 
crossbreeding type I diabetic Akita  mice with our established transgenic mice overexpressing 
rat Cat in RPTCs. In another study, Akita mice were treated with Ang 1-7 or combination of 
Ang 1-7 and its antagonist, A779, to investigate the relations between Ang 1-7 action, systolic 
hypertension (sHTN), oxidative stress, kidney injury, ACE2 and Mas receptor expression. 
Our results showed that overexpression of Cat attenuated renal oxidative stress; prevented 
hypertension; ameliorated glomerular filtration rate, albuminuria, kidney hypertrophy, 
tubulointerstitial fibrosis, and tubular apoptosis; and suppressed profibrotic and proapoptotic 
 vii 
gene expression in RPTCs of Akita Cat-Tg mice compared with Akita mice. Furthermore, 
overexpression of Cat in RPTCs of Akita mice normalized renal ACE2 expression and urinary 
Ang 1–7 levels.  
On the other hand, Ang 1-7 administration prevented systemic hypertension, normalized 
urinary albumin/creatinine ratio and attenuated glomerular hyperfiltration without affecting 
blood glucose levels in Akita mice. Furthermore, Ang 1-7 treatment also attenuated oxidative 
stress and the expression of NADPH oxidase 4, Agt, ACE, transforming growth factor-β1 
(TGF-β1) and collagen IV, and increased the expression of ACE2 and Mas receptor in Akita 
mouse kidneys. These effects were reversed by co-administration of A779.  
These data demonstrated that Cat overexpression prevents hypertension and progression of 
nephropathy and highlight the importance of intrarenal oxidative stress and ACE2 expression 
contributing to hypertension and renal injury in diabetes. Furthermore, our data suggest that 
Ang 1-7 plays a protective role in hypertension and RPTC injury in diabetes, predominantly 
through decreasing renal oxidative stress-mediated signaling and normalizing ACE2 and Mas 
receptor expression. Our results also indicate Ang 1-7 as a potential therapeutic agent for 
treatment of systemic hypertension and kidney injury in diabetes. Therefore, Ang 1-7 mediates 
the major protective role of ACE2 in the hypertension and DN. 
 
Key words:  Kidney, renin-angiotensin system, angiotensin-converting enzyme 2, catalase, 
hypertension, Angiotensin 1-7, Mas receptor, diabetic nephropathy, hypertension, apoptosis, 
tubulointerstitial fibrosis, reactive oxygen species, NADPH oxidase 
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Chapter 1: Introduction 
 
  
2 
 
1.1 Renal physiology and histology 
 
1.1.1 Renal physiology 
The kidney participates in whole-body homeostasis, regulating acid-base balance, extracellular 
fluid volume, electrolyte concentrations and blood pressure. It produces urine, in which 
various metabolic waste products are removed. Urine is continuously formed from an 
ultrafiltrate of plasma from which glucose, amino acids, water and other essential substances 
have been reabsorbed. Specific secretion also occurs to transfer the substances that are present 
in great excess or are natural poisons. The kidney also maintains the proper balance of water 
and minerals, including electrolytes, in the body, even though the dietary intake of water and 
salt may vary. In addition, the kidney can synthesize some hormones including 1,25 OH 
vitamin D, erythropoietin, and renin. 
Nephron is defined as the essential structural and functional unit of the kidney. In the 
structural context, each nephron consists of a renal corpuscle (glomerulus and Bowman's 
capsule), and a tubule unit including proximal tubule, loop of Henle and distal tubule (Figure 
1-1). There are approximately 1.7 to 2.4 million nephrons in both kidneys of normal adult. 
1.1.2 Renal histology 
At the beginning of the nephron, the glomerulus is a network of capillaries that receives its 
blood supply from an afferent arteriole of the renal circulation. The glomerulus is surrounded 
by Bowman's capsule, which is an expansion at the closed end of a renal tubule. The blood 
plasma is filtered through the capillaries of the glomerulus into the Bowman's capsule. The 
ultrafiltrate collects within the Bowman's capsule and then flows into the proximal tubule.  
The glomerulus drains into an efferent arteriole. 
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5 
domain. The slit diaphragm is a cell–cell junction that shares features of tight and adherens 
junctions [5] and displays anatomical regularity, with a gap of 40 nm thought to restrict the 
passage of proteins any larger than albumin. The gap is cross-linked by extracellular proteins, 
of which the transmembrane protein nephrin forms a major component, forming globular 
strands of 35 nm in length [6]. 
There is a consensus that podocyte response to injury follows a similar path regardless of the 
original cause of podocyte injury (genetic, environmental, or both). Podocyte injury leads to 
effacement of the podocyte foot processes, i.e. loss of membrane extension, which involves 
reorganization of the actin network. These early structural changes within the podocyte result 
in proteinuria. If these changes are not reversed, podocyte detachment and loss occurs with 
subsequent development of obliteration of the urinary space, segmental glomerulosclerosis, 
and finally, end-stage renal failure [7]. Growth factor receptors such as vascular endothelial 
growth factor (VEGF) and transforming growth factor β (TGF-β1), G protein-coupled 
receptors (GPCRs) such as the angiotensin type 1 receptor (AT1R), signalling through 
integrins, and ion channels, like the TRPCs, have been implicated in early podocyte injury [8]. 
Nephrin assembles into a zipper-like isoporous filter structure of the podocyte slit diaphragm, 
forming a part of the size-selective glomerular filtration barrier (Figure 1-3) [9]. Patients with 
nephrin mutations, which were originally found in cohorts of Finnish patients (Finnish-type 
nephrotic syndrome), display the earliest and most severe clinical phenotype, indicating an 
essential role for this protein in the intact filtration [10]. Abnormalities in nephrin expression 
have also been demonstrated in other human proteinuric renal diseases and in a range of 
experimental renal diseases associated with proteinuria [11, 12]. 
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8 
concentration. The electrochemical gradient thus created provides the driving force for 
ongoing transport of Na+ into the cell across the apical membrane, allowing for glucose to be 
concurrently cotransported by SGLTs. The specific facilitative glucose transporter, GLUT, on 
the basolateral membrane then transports the glucose into the interstitium [16] (Figure 1-5). 
The proximal tubule can only reabsorb a limited amount of glucose. Under normal conditions, 
the proximal tubule reabsorbs approximately 180 g of glucose from the glomerular filtrate 
each day. When the blood glucose level exceeds renal threshold of glucose (160–180 mg/dl), 
the proximal tubule becomes overloaded and begins to excrete glucose in the urine. This 
condition is termed glycosuria [17]. 
Sodium is freely filtered at the glomerulus. In the proximal convoluted tubule, 50% of the 
filtered sodium is reabsorbed. Although in the apical membrane there are 20 different sodium 
transporters, most of which couple to “substrates” (such as amino acids and carbohydrates), 
collectively they mediate only 10% of in sodium reabsorption the proximal tubule. The 
sodium-hydrogen exchanger, NHE3, mediates the majority of Na+ reabsorption [18] (Figure 1-
6B). 
 
1.1.2.4 Other components of a nephron 
 (a) Henle’s loop 
Named after its discoverer, F. G. J. Henle, the loop of Henle's main function is to establish an 
osmotic gradient in the medulla of the kidney for water reabsorption. The loop of Henle has 
three distinct regions: the thin descending limb, the thin ascending limb and the thick 
ascending limb (TAL). In the TAL, almost all sodium transport results directly or indirectly 
from Na+-K+-2Cl- cotransporter (NKCC2) and ~20% of the filtered load is reabsorbed. The 
 loop o
tubule 
 
 
 
Figure
mecha
loop of
 
 
(b) Dis
The di
convol
f Henle as 
fluid passes
 1-6. A: p
nisms of so
 Henle (C),
tal tubules 
stal tubule i
uted tubule
a whole rea
 through H
ercentage s
dium reabso
 the distal c
s lined with
. Sodium 
bsorbs 30–
enle’s loop,
odium reab
rption are 
onvoluted t
 simple cub
reabsorptio
9 
40% of the
 it becomes
sorption o
shown in th
ubule (D), 
oidal cells
n in the d
 filtered so
 hypo-osmo
ver the len
e proximal 
and the coll
 that are sho
istal tubule
dium [18] (
tic. 
gth of the 
tubule (B),
ecting duct 
rter than th
 is mediate
Figure 1-6C
nephron. P
 the thick a
(E). 
ose of the p
d by the 
 
). After 
 
rincipal 
scending 
roximal 
thiazide-
 sensitiv
also, to
collect
 
 
  
 
Figure
 
(c) Jux
 
The JG
glomer
filtratio
mesang
muscle
decrea
e NaCl cot
 a lesser e
ing duct con
 1-7. The ju
taglomerula
 apparatus
ular affere
n rate of th
ial cells (
 cells of g
se in the s
ransporter (
xtent, by s
nects the n
xtaglomeru
r (JG) appa
 is a specia
nt arteriole
e glomerulu
Figure 1-7)
lomerular a
odium chlo
NCC) (Fig
odium-hydr
ephrons to 
lar apparatu
ratus 
lized struc
 and its m
s. It consis
. JG cells,
rterioles a
ride conce
10 
ure 1-6D), w
ogen exch
the ureter.
s [20] 
ture formed
ain functio
ts of JG cel
 also calle
nd can sec
ntration in 
hich is reg
ange (NHE
 by the di
n is to reg
ls, macula d
d Granular
rete renin. 
the distal 
ulated by a
2). After th
stal convol
ulate bloo
ensa cells 
 cells, are 
The macul
tubule and 
ldosterone 
e distal tub
uted tubule
d pressure 
and extraglo
specialized
a densa sen
causes JG
 
[19], and 
ule, the 
 
 and the 
and the 
merular 
 smooth 
ses any 
 cells to 
 release
the aff
filtratio
cells lo
 
1.2 Pat
In the 
causes
cause. 
turning
fibrosi
appear
 
Figure 
cortex, 
 
 renin. In r
erent arteri
n rate. Ext
cated near 
hological c
early stages
. However, 
The cortex 
 atrophic. 
s and thicke
ance of "thy
1-8. The m
black arrow 
esponse to 
ole, reduci
raglomerula
the macula 
hanges in k
 of kidney 
the patholo
is fibrotic, 
There are 
ned arterie
roidization
icroscopic a
indicates art
increased s
ng blood fl
r mesangia
densa, but t
idney disea
disease, his
gical altera
with most g
scattered ch
s. Tubular l
" (Figure 1-
ppearance o
ery, and blac
11 
odium, the
ow to the 
l cells, also
heir functio
ses 
tological ch
tions of kid
lomeruli b
ronic infla
umens are 
8). 
f end-stage 
k arrow hea
 macula de
glomerulus
 called Lac
n remains u
anges can 
neys at end
ecoming sc
mmatory c
dilated and 
renal disea
d indicates g
nsa cells tr
 and thus 
is Cells, ar
nclear. 
vary becaus
-stage are s
lerotic and 
ell infiltrat
filled with 
se (ESRD). 
lomeruli. [21
igger contra
also the glo
e flat and e
e of many 
imilar rega
the affiliate
es, tubuloin
pink cast, g
 
Red arrow 
] 
 
ction of 
merular 
longated 
different 
rdless of 
d tubule 
terstitial 
iving an 
indicates 
 The ki
or less
blurred
 
 
Figure 
 
 
1.3 Ch
1.3.1 C
CKD i
the uri
albumi
of kidn
three m
kidney
kidney
ESRD
work, 
dneys in ES
 scattered, 
 boundary 
1-9. A: Norm
ronic kidne
KD and GF
s defined a
ne or protei
nuria; other
ey function
onths or m
 damages 
s function a
, wherein t
such as rem
RD are usu
shallow cor
between the
al kidney; B
y diseases (
R 
s the presen
nuria, or, m
 blood or u
 (as eviden
ore [22]. C
are, or the 
t below 15 
here is tota
ove waste o
ally small,
tical scars.
 cortex and
: Kidneys in
CKD) 
ce of kidn
ore specific
rine marker
ced by redu
KD can be 
level of d
percent of t
l or near-to
r excess flu
12 
 firm, and p
Cross-secti
 medulla. (F
 ESRD [13]
ey damage 
ally, elevat
s; or pathol
ced glomer
divided into
ecrease in 
heir norma
tal loss of
id from the
ale and the
on of the k
igure 1-9)
 
(most com
ed albumin
ogical abno
ular filtratio
 five stage
kidney fun
l capacity, s
 kidney fun
 blood. Wh
 surface is 
idney revea
[21].  
monly evid
: creatinine
rmalities), 
n rate or G
s, dependin
ction [23] 
tage 5 CKD
ction, they
en CKD de
granular w
ls a thin co
enced by p
 ratio in the
or a decrea
FR), for a p
g on how se
(Table 1-1
, also refer
 cannot ef
velops into 
 
ith more 
rtex and 
 
rotein in 
 urine or 
sed level 
eriod of 
vere the 
). When 
red to as 
fectively 
ESRD,  
 Table 1
 
 
Table 1
 
T
20- 
30- 
40- 
50- 
60- 
70
 
-1. The 5 sta
-2. Average 
ABLE : AVER
AGE 
(Years) 
29 
39 
49 
59 
69 
+ 
ges of chron
estimated G
AGE MEASUR
 
 
 
 
 
ic kidney di
FR by age [2
ED  GFR BY A
AVERAGE M
13 
sease (CKD)
4]. 
GE IN PEOPL
EASURED  G
 [23] 
E WITHOUT 
FR (mL/min/1.
116 
107 
99 
93 
85 
75 
CKD2 
73  m2) 
 
 
 dialysi
with ag
when e
decade
 
1.3.2 In
Inciden
a given
popula
(point 
 
         
Figure 
 
Total i
patient
cases p
2010, t
s or a kidne
e, even in 
valuating k
 in the gene
cidence, pr
ce is defin
 period of 
tion at a sp
prevalence)
1-10. Causes
ncident dia
s received a
er million 
o 348 [25]
y transplan
people with
idney func
ral populat
evalence an
ed as the nu
time. Prev
ecific perio
.  
 of ESRD [1
lysis cases 
 pre-emptiv
population,
. As of Dec
t is necessa
out kidney
tion. Table
ion [24]. 
d causes o
mber of new
alence of C
d of time (
3] 
in USA ros
e transplan
 which has 
ember 31, 
14 
ry to surviv
 disease, it 
 1-2 shows
f ESRD 
ly-diagno
KD is the 
period prev
e 0.27 perc
t as their fir
been relati
2010, preva
e. However
is necessary
 the averag
sed patients
number of 
alence) or 
 
ent in 2010
st ESRD m
vely steady
lent popula
, since GFR
 to take thi
e values of
 in a specif
CKD cases
at a particu
, to 114,08
odality. Th
 since 2000
tion includ
 declines g
s into cons
 estimated 
ic populatio
 existing in
lar momen
3, while on
e rate of ne
, fell 2.0 p
ed 383,992
 
radually 
ideration 
GFR by 
n during 
 a given 
t in time 
ly 2,863 
w ESRD 
ercent in 
 patients 
 
 
15 
on hemodialysis and 29,733 on peritoneal dialysis, as well as 179,361 with a kidney 
transplant; the total treated ESRD population thus rose to 593,086 [25]. 
Diabetes has become the most common single cause of end-stage renal disease (ESRD) in the 
U.S.A, accounting for ~44% of new cases of treated ESRD in 2011. The second most common 
cause is high blood pressure or hypertension [26] (Figure 1-10). 
 
1.4 Diabetes Mellitus (DM) 
1.4.1 Prevalence and cost of diabetes 
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting 
from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of 
diabetes is associated with long-term damage, dysfunction, and failure of a variety of organs, 
especially the kidneys, nerves, eyes, heart, and blood vessels [27]. The vast majority of cases 
of diabetes fall into two broad etiopathogenetic categories: type 1 diabetes (T1D) and type 2 
diabetes (T2D).  
T1D is characterized by the destruction of the pancreatic beta cells, resulting in absolute 
insulin deficiency. This is usually due to autoimmune-mediated destruction of the beta cells 
(type 1A). Islet cell antibodies (ICA) or other islet autoantibodies (such as antibodies to 
GAD65, insulin, IA-2) can be found in the serum [27]. However, some patients have no 
evidence of autoimmunity and have no other known cause for beta-cell destruction (type 1B). 
T2D is by far the most common type of diabetes in adults and accounts for ~90–95% of those 
with diabetes.  The patients have insulin resistance and usually have relative (rather than 
absolute) insulin deficiency. Most of them are obese, and obesity itself causes some degree of 
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18 
blood vessels and include nephropathy, retinopathy and neuropathy. The macrovascular 
complications affect larger blood vessels, including cardiovascular diseases, such as heart 
attacks and strokes. Many hypotheses have been proposed to explain underlying mechanisms. 
A large body of evidence indicates that oxidative stress is the common denominator link for 
the major pathways involved in the development and progression of diabetic micro- as well as 
macrovascular complications of diabetes [33]. 
 
1.4.3 Reactive Oxygen Species (ROS) and oxidative stress 
 
ROS are composed of a series of oxygen intermediates, including the free radical superoxide 
anion (O2−), the highly reactive hydroxyl free radical (HO·), the nonradical hydrogen peroxide 
(H2O2), peroxynitrite (ONOO−), hypochlorous acid (HOCl) and lipid radicals. Excessive 
amounts of ROS, overwhelming the detoxification capacity of various endogenous anti-
oxidative defensive mechanisms, oxidize various tissue biomolecules, such as DNA, protein, 
lipids and carbohydrates, and this disastrous state has been commonly referred to as an 
oxidative stress [33]. In mammalian cells, potential sources of ROS include mitochondrial 
respiratory chain, NADH/NADPH oxidases, xanthine oxidase, NO synthase and other certain 
hemoproteins. 
1.4.3.1 Mitochondrial origin of ROS  
Glucose generates ATP, NADH and FADH2 via glycolysis and oxidative phosphorylation. 
The electrons from NADH or FADH2 are transferred to molecular oxygen (O2) in the 
mitochondrial respiratory chains complex I – IV to generate ATP. During this process, most of 
the O2 is reduced to water under normal physiological states, and less than 1% of O2 is 
converted to superoxide anion, O2−. However, under mitochondrial dysfunctional or 
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fibroblast, thick ascending limb, distal convoluted duct including macula densa cells and 
cortical collecting ducts; Nox-2 in podocytes, mesangial cell and endothelium; Nox-4 in 
glomerulus, proximal tubule and distal convoluted tubule; and Nox-3 in fetal kidney [39]. 
Of the renal Noxes, Nox4 is most abundantly expressed and hence was originally termed 
Renox [40, 41]. NOX4 is a p22phox-dependent enzyme, however it does not require cytosolic 
subunits for its activity [37]. NOX4 requires p22phox, but in reconstitute systems it is 
constitutively active without the requirement for other subunits. In native NOX4-expressing 
cells, however, a Rac requirement for activation has been documented [37]. 
The Nox5 gene is absent from the mouse and rat genomes, making the use of conventional 
animal models unfeasible. Unlike other Nox family members, Nox5 does not require 
membrane-bound or cytosolic components, such as p22phox or p47phox, for its activity, but is 
tightly regulated by changes in intracellular calcium levels [42]. Interestingly, Holterman and 
colleague [42] recently generated transgenic mice expressing human Nox5 in a podocyte-
specific manner (Nox5pod+). Nox5pod+ mice exhibited early onset albuminuria, podocyte foot 
process effacement, GBM thickening, interstitial fibrosis, and elevated systolic blood pressure 
(BP). Subjecting these mice to STZ-induced diabetes further exacerbated these changes. 
Furthermore, kidney biopsies from diabetic patients showed increased NOX5 expression 
compared with nondiabetic subjects. 
 
1.4.3.3 SOD, Catalase, GPX and Nrf2 
(a) SOD 
Superoxide dismutase (SOD) is the main defense against O2•−, catalyzing its dismutation to 
H2O2 and O2. There are three isoforms in mammalian cells: SOD1 (Cu, Zn SOD) is located in 
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the cytoplasm, SOD2 (MnSOD)  is in the mitochondria, and SOD3(extracellular  SOD;EC-
SOD) is extracellular [43]. Mitochondria are both a major source of ROS production from 
respiratory chains as well as a major target of ROS-induced cellular injury. Thus, 
mitochondrial Mn-SOD is thought to play an important role in cellular defense against 
oxidative damage by ROS [44]. Complete loss of the gene encoding MnSOD results in a lethal 
phenotype with some live births [45, 46], but heterozygous knockout mice have a normal 
lifespan [47]. Cu, Zn SOD is the major isoform of SOD in the renal cortex and glomeruli, 
accounting for more than 90% of total SOD activity in these tissues [48]. Deficiency of SOD1 
accelerated renal injury in STZ-induced diabetic mice , while treatment of these mice  with the 
SOD mimetic tempol for 4 weeks suppressed albuminuria, glomerular transforming growth 
factor β, collagen α1(IV), nitrotyrosine, and glomerular superoxide [48]. 
 
(b) Catalase (Cat) 
Catalases are enzymes that catalyse the conversion of H2O2 into water and oxygen according 
to the equation: 2H2O2 → 2H2O + O2. They use either an iron or manganese cofactor with a 
high catalytic rate. Cat is encoded by a single gene, which is highly conserved among species. 
It is expressed in all mammalian tissues and can be found in the liver, kidneys and erythrocyte 
with high concentration [49]. High Cat activity is detected in peroxisomes. Cat is also found in 
the cytosol of erythrocytes [50]. Cat is a tetramer of four polypeptide chains, each over 500 
amino acids long. Cat contains four porphyrin heme (iron) groups that allow the enzyme to 
react with the hydrogen peroxide[51]. In the kidney, Cat is localized predominantly in the 
cytoplasm of proximal tubules of the superficial cortex. Cat was not detected in the glomeruli, 
loop of Henle, distal tubules, and collecting ducts [52]. Cat deficiency in STZ-induced diabetic 
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mice increased mitochondrial ROS and fibronectin expression in response to free fatty acids, 
which were effectively normalized by catalase overexpression or N-acetylcysteine [53]. 
 
(c) Glutathione peroxidases (GPxs) 
The “classical” glutathione peroxidase, now called GPx1, was first discovered as an 
erythrocyte enzyme that specifically reduces H2O2 by GSH, but later shown to reduce a broad 
scope of organic hydroperoxides [54]. There are eight distinct GPxs in mammals, most of 
which are selenoproteins. Only GPx1, 3 and 4 have been functionally characterized to some 
extent [49]. Low levels of both GPx1 and GPx3 are associated with the development of 
vascular disease. The patients of CVD with low erythrocyte GPx1 activities had increased 
recurrent events [55]. Lack of functional GPx1 accelerates diabetes-associated atherosclerosis 
via upregulation of proinflammatory and profibrotic pathways in apolipoprotein E (ApoE) 
knockout mice [56], whereas ebselen, a GPx mimetic, could attenuate diabetic nephropathy 
and diabetes-associated atherosclerosis in ApoE/GPx1 double knockout mice [57]. 
 
(d) Nuclear factor erythroid 2-related factor (Nrf2) 
The genes encoding SOD, Cat and GPx contain antioxidant response elements (AREs) in their 
regulatory regions. Nrf2 is the principal transcription factor that binds to the ARE. Actin-
tethered Keap1 is a cytosolic repressor that binds to Nrf2, keeps it in the cytoplasm, and 
promotes its proteasomal degradation [58]. Nrf2 activators modify specific cysteine residues 
of Keap1 and cause conformational changes that render Keap1 unable to repress Nrf2. Once 
released Nrf2 migrates into the cell nucleus, binds to AREs and activates the transcription of 
antioxidant genes [59]. Bardoxolone methyl is among the first orally available antioxidant 
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Nrf2 activators [60]. Bardoxolone methyl was first advanced into the clinic to assess its 
anticancer properties. In phase 1 trials that included cancer patients, bardoxolone methyl 
decreased serum creatinine levels, with a corresponding improvement in estimated glomerular 
filtration rate (eGFR) [61]. Phase 2  trials,  including persons with T2D and stage 3b or 4 
CKD,  have shown that bardoxolone methyl can reduce the serum creatinine concentration for 
up to 52 weeks [62]. However phase 3 trials showed that among patients with T2D and stage 4 
CKD, bardoxolone methyl did not reduce the risk of ESRD or death from cardiovascular 
causes. Moreover, significantly increased risks of heart failure and of the composite 
cardiovascular outcome prompted termination of the trial [62]. 
 
1.5 Diabetic Nephropathy (DN) 
The earliest clinical evidence of nephropathy is the appearance of low but abnormal levels 
(≥30 mg/day or 20 µg/min) of albumin in the urine, referred to as microalbuminuria, and 
patients with microalbuminuria are referred to as having incipient nephropathy. Without 
specific interventions, ~80% of subjects with T1D who develop sustained microalbuminuria 
will  progress to overt nephropathy or clinical albuminuria (≥300 mg/24 h or ≥200 µg/min) 
[63]. Recent findings showed that there existed another marker of early DN, early renal 
function decline (ERFD), i.e. the presence of a progressive loss of GFR over time even if it 
remains in the normal range [64]. There are three major histologic changes in the glomeruli in 
diabetic nephropathy: mesangial expansion; glomerular basement membrane thickening; and 
glomerular sclerosis [65]. An abnormality in late stage is Kimmelstiel-Wilson lesion and has 
been considered as a hallmark of DN (Figure 1-17). This lesion has a nodular appearance, with 
an acellular, hyaline matrix core, surrounded peripherally by sparse, crescent-shaped 
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 After 20 years of diabetes duration, around 30% of T1D patients develop DN. Over 5% of 
newly diagnosed T2D patients already have renal dysfunction. Another 25-40% of T2D 
patients will develop DN after 25 years of diabetes; they will also manifest a high tendency to 
progress to ESRD. 
 
1.5.1 Pathogenesis of DN 
Although the pathogenesis of DN is not completely understood, several factors are closely 
relevant to DN. Briefly, they are: (1) Hypertension and hemodynamic factors; (2) augmented 
ROS formation; (3) enhanced activity of the aldose reductase pathway; (4) increased 
formation of AGEs; (5) PKC activation; (6) Hexosamine pathway flux; (7) heightened activity 
of growth factors, TGF-β1; (8) activation of cytokines (e.g. angiotensin II or Ang II). The 
relationship of these major factors to the development of DN is discussed below. 
 
1.5.1.1 Hypertension and DN 
Diabetic patients who progressed to albuminuria had higher baseline arterial pressures than the 
patients who stayed normoalbuminuria [68]. Patients with T2D and hypertension have a 
sevenfold greater risk of progression to ESRD compared to patients with T2D and normal 
blood pressures [69].  
Clinical studies have established that tight control of blood pressure can slow kidney disease 
progression in both T1D and T2D [70, 71]. Studies in recent years have focused on the 
primary prevention of microalbuminuria [72]. Tight achievement of recommended blood 
pressure goals may also prevent or delay the new onset of microalbuminuria and in doing so, 
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halt the development of later stages of overt nephropathy. As a result, new preventative 
strategies for hypertension management continue to be explored [73]. 
At diagnosis of T2D, hypertension is already present in 50% of patients. Sixty percent of 
hypertensive patients with T2D develop diabetic kidney disease. In T1D patients with 
normoalbuminuria, the prevalence of hypertension varied between that of the general 
population (4%) [74] and 19%, as reported in a cross-sectional Danish study [75]. In T1D, 
hypertension typically occurs in those with microalbuminuria or overt kidney disease. A large 
number of epidemiologic studies and clinical trials have established that high blood pressure 
(particularly systolic) is a risk factor for accelerated progression in proteinuric conditions such 
as diabetic CKD.  
 
1.5.1.2 Oxidative stress in DN 
The cell susceptibility to glucose-induced toxicity is determined by its expression of glucose 
uptake mechanisms and by the ability of these cells to downregulate glucose uptake in the 
setting of hyperglycemia [76]. Enhanced glucose uptake has been identified in many of the 
cell populations within the diabetic kidney, including glomerular epithelial cells, mesangial 
cells, and proximal tubular cells [77]. As mentioned before, more ROS have been generated 
by mitochondria.  
Another important source of ROS is NADPH oxidase. Nox4 is the most abundant NOX in the 
kidney.  The levels of both NOX4 and p22phox mRNA were increased in the kidney of 
streptozotocin (STZ)-induced diabetic rats as compared with control rats. Immunostaining 
analysis revealed that the expression levels of NOX4 and p22phox were clearly increased in 
both distal tubular cells and glomeruli from diabetic rats [78]. Nox4 protein expression was 
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increased in diabetic kidney cortex compared with non-diabetic controls and antisense 
oligonucleotides for Nox4 downregulated NOX4, reduced whole kidney and glomerular 
hypertrophy, and attenuated fibronectin expression [79]. Although Nox2 levels are not 
affected in the renal cortex from T2D db/db mice [80], Nox2 is increased in the cortex from 
T1D rats [79]. However, lack of Nox2 does not protect against diabetic kidney disease in T1D 
and this may be due to upregulation of renal Nox4 [81]. Data from Nox4 knockout mice are 
contradictory. In models of transient or permanent cerebral ischemia, Nox4-deficient mice and 
mice treated with the Nox4 inhibitor VAS2870 were protected from oxidative stress, neuronal 
apoptosis, and blood-brain barrier leakage [82]. On the contrary, Schroder et al [83] showed 
that in global Nox4 deficient mice, ischemia-induced angiogenesis is attenuated and that in 
tamoxifen-inducible Nox4 deficient mice, Ang II–mediated aortic inflammation, vascular 
hypertrophy, and endothelial dysfunction are exaggerated. Thus further studies are needed to 
unriddle the Nox4 paradox. 
 
1.5.1.3 Aldose reductase and DN 
In the setting of hyperglycemia there is increased shuttling of glucose metabolism into the 
sorbitol/polyol pathway [84]. The glucose is oxidized into sorbitol by the enzyme aldose 
reductase, a reaction that requires NAD(P)H. Sorbitol is subsequently reduced to fructose by 
sorbitol dehydrogenase, during which NADH is generated (Figure 1-18). Since NAD(P)H is 
required for the glutathione reductase reaction in which glutathione disulfide is reduced to 
glutathione, the consumption of NAD(P)H will finally reduce the levels of cellular glutathione 
and ultimately also the antioxidant activity. Furthermore, the newly generated NADH is 
utilized by the respiratory chain reaction resulting in excess generation of superoxide anion 
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In mesangial cells cultured in high concentration of glucose, enhanced fibronectin 
accumulation is mediated by  a sustained activation of PKC and prevented by calphostin C (a 
potent inhibitor of PKC) [96, 97]. Some studies have demonstrated enhanced PKC activity in 
the glomeruli of STZ-induced diabetic rats [101, 102]. Furthermore, the PKCα isoform has 
been found to be significantly increased in the glomeruli, interstitial capillaries and endothelial 
cells of larger arteries in diabetic rats [98].  
The implication of PKC causing elevated production of ECM and TGF-β is further supported 
by several reports showing that LY333531 (PKCα-selective inhibitor) prevents 
hyperglycemia-increased ECM production and TGF-β expression in mesangial cells [99].   
Menne et al reported that protein kinase C alpha (PKCα)-deficient mice are resistant to the 
development of albuminuria under diabetic conditions [103]. They also found that PKCα is 
involved in reduction of nephrin surface expression and in PKCα-/- mice, hyperglycemia-
induced downregulation of nephrin was prevented [104]. 
 
1.5.1.6 Hexosamine pathway flux and DN 
Hexosamine pathway is required for proteoglycan synthesis and the formation of O-linked 
glycoprotein and provides the substrate, UDP-N-acetylglucosamine. When intracellular 
glucose is high, it enters the glycolytic pathway. The intermediate fructose-6-phosphate (Fruc-
6-P) is converted to glucosamine-6-phosphate by the enzyme glutamine: fructose-6-phosphate 
amidotransferase (GFAT) (Figure 1-21). Glucosamine-6-phosphate is then converted to UDP-
N-Acetylglucosamine. Specific O-GlcNAc transferases use this for post-translational 
modification of specific serine and threonine residues on cytoplasmic and nuclear proteins by 
O-linked N-Acetylglucosamine. O-GlcNAcylation of the transcription factor Sp1 augments 
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TGF-β is one effector molecule that has been studied extensively as a major mediator of the 
hypertrophic and prosclerotic changes in diabetic kidney disease [111]. TGF-β1stimulates the 
synthesis of key extracellular matrix molecules including type IV collagen, type I collagen, 
fibronectin, and laminin [112]. TGF-β1 I also decreases matrix degradation by inhibiting 
proteases as well as activating protease inhibitors (e.g. Plasminogen activator inhibitor-1). In 
addition, TGF-β1 I promotes cell–matrix interactions by elevating integrins, the cell surface 
receptors for matrix [110]. 
 
1.5.2 Apoptosis and diabetic kidneys 
1.5.2.1 General apoptosis pathways 
Apoptosis is the nature’s preprogrammed form of cell death. Apoptosis occurs normally 
during development, when damaged tissues are repaired, and as a homeostatic mechanism to 
maintain cell populations in tissues [113]. The classical understanding of apoptosis suggests 
that it provides a benign means for the necessary clearance of cells that are no longer needed 
or no longer functional. The current model holds that apoptotic cells do not elicit an immune 
response nor have any effect on surrounding cells. 
The intrinsic apoptotic pathway is activated in response to various stimuli, such as DNA 
damage, hypoxia, and endoplasmic reticulum (ER) stress. This pathway is mainly regulated by 
the anti-apoptotic (Bcl-2, Bcl-XL), the pro-apoptotic (Bax, Bak), and the BH3-only proteins 
(Bad, Bid, Bim…).  When Bax, Bid, and Bim are activated, they translocate to the 
mitochondria to induce apoptosis, either by binding to Bcl-2, Bcl-XL via BH3 domains and 
antagonizing their anti-apoptotic functions or through the permeabilization of the 
mitochondrial membrane. Permeabilization of the mitochondrial membrane releases 
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(TRADD) recruits and activates caspase -8 to form a death-inducing signalling complex 
(DISC). DISC can transduce the death signal directly by activating the effector caspases-3 and 
-7, or indirectly via cleavage of Bid, which translocates to the mitochondria, leading to 
mitochondrial outer membrane permeabilization, subsequent release of cytochrome c, 
activation of caspase 9 and ultimately activation of caspase -3 and -7 [114, 115].  
 
1.5.2.2 Apoptosis in diabetic glomeruli 
 
Diabetes can cause the apoptosis of podocytes and mesangial cells. Susztak et al.[116] have 
shown that podocyte apoptosis increased markedly with onset of hyperglycemia in Akita mice 
and db/db mice. Podocyte apoptosis coincided with the onset of urinary albumin excretion and 
preceded significant podocytes loss in Akita (37% reduction) and db/db (27% reduction) mice. 
In vitro study demonstrated that high glucose led to activation of proapoptotic p38 MAPK and 
caspase 3 and to apoptosis of conditionally immortalized podocytes. They also found that ROS 
stimulated by high glucose play an important role upstream in this process and various 
inhibitors of ROS could reduce podocyte apoptosis and podocyte depletion in vitro and in 
vivo. 
In human and murine renal mesangial cells, high glucose levels caused an increased Bax/Bcl-2 
ratio, cytochrome c release from mitochondria and subsequent the proapoptotic caspase-3 
activation [117, 118]. 
 
1.5.2.3 Apoptosis in diabetic tubules 
Hyperglycemia by infusing 10% glucose into male Wistar rats for 300 minutes led to 
fragmentation in the DNA of proximal tubular cells [119]. Apoptosis has been found in renal 
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In 2000, two independent groups [127, 128] discovered the new member of RAS, ACE2.  
The main product of ACE2 is angiotensin-(1–7) (Ang 1–7), which is now recognized as a 
vasodilatory peptide. It has been established that Ang 1–7 acting on its own unique receptor 
(the Mas receptor) mediates vasodilation, antiproliferation, and apoptosis [129], therefore 
opposing the effects of Ang II. Thus, the new arm of the RAS, the ACE2-Ang-Mas axis, has 
been shown to be effective at counterregulating the effects of the classic ACE-Ang II-AT1R 
axis (Figure 1-27).  
 
1.6.2 Local RASs 
In parallel with the recognition of an increasing number of novel RAS components, emerging 
evidence has demonstrated the importance of local RAS in the brain, heart, adrenal glands, 
vasculature, and kidneys. In particular, the renal RAS is unique because all of the components 
of the RAS are present within the kidney [125].  
 
Proximal tubular cells express both messenger RNA (mRNA) and protein for all components 
of the RAS [130-132] (Figure 1-28). In the lumen of the proximal tubule, Ang II levels are in 
the nanomolar range, which is 1,000-fold greater than those in plasma [133, 134]. In addition, 
the glomeruli also contain a local RAS. Components of the RAS have been detected in 
glomeruli in both humans and animals [135, 136] and Ang II concentrations in glomerular 
ultrafiltrate are significantly higher than in plasma [133, 137]. 
Increased intrarenal Ang II levels have been shown in several models of hypertension, 
including chronic Ang II infusions and two-kidney–one-clip Goldblatt hypertension [138]. 
Overproduction of intrarenal Ang II leads to the development of hypertension and renal injury 
[138, 139]. 
  
 
 
Figure 
hyperte
formati
stimula
afferent
 
1.6.3 In
1.6.3.1
To stu
animal
1.6.3.1
(a) Mic
In the 
C57BL
contain
1-28. Casca
nsion, the k
on and spill
tion of tubul
 arteriole; E
trarenal RA
 Animal mo
dy the effe
s have been
.1 RAS KO
e lacking r
human and
/6, also co
 two (Ren1
de of intratu
idney main
over into d
ar ACE. PT 
A, efferent a
S activatio
dels of RA
cts of RAS
 generated.
 mice 
enin 
 the rat, th
ntain one 
d and Ren2
bular RAS 
tains intrare
istal nephron
indicates pro
rteriole.[140
n  
S activation
 on the hy
 
ere is only
renin gene 
) [141]. On 
44 
in Ang II–d
nal Ang II 
 segments 
ximal tubul
] 
  
pertension 
 a single re
(Ren1c), w
one hand, k
ependent hy
formation, 
coupled wit
e; IC, interca
and kidney
nin gene. 
hereas othe
nockout of
pertension. 
enhanced p
h enhancem
lated cell; P
 damage, g
Some strain
rs, such as
 the Ren2 g
In Ang II–d
roximal tub
ent of CD r
C, principal 
enetically m
s of mice,
 DBA2/J a
ene in 129/O
 
 
ependent 
ule AGT 
enin and 
cell; AA, 
odified 
 such as 
nd 129, 
la mice 
 
 
45 
has no discernible effect on blood pressure [142]. On the other hand, knockout of Ren1d  in a 
two renin-gene strain results in the reduction of blood pressure in females, together with 
altered morphology of the macula densa of the kidney’s distal tubule and with complete 
absence of juxtaglomerular cell granulation [143].  
Knockout of Ren1 in a single renin-gene strain are hypotensive and polyuric, but 
heterozygotes are indistinguishable from wild-type [144]. 
(b) Mice lacking Agt 
Angiotensinogen-deficient C57Bl/6 mice exhibited hypotension (66.9 mm Hg, compared with 
wild-type 100.4 mm Hg) [145], reduced survival rates of newborns, abnormal kidney 
morphology, and impaired blood–brain barrier function after cold injury [146]. Stec et al [147] 
generated a transgenic model in which exon 2 of the human Agt gene is flanked by loxP sites 
(hAgtflox) so that this region of the gene can be deleted by the Cre-recombinase (delivered by 
intravenous administration of adenovirus, which mainly infects the liver). Blood pressure 
decreased by 25 mm Hg from baseline by day 8 post-administration, paralleled by a 
significant acute decrease in circulating Agt within 5 days. 
(c) Mice lacking ACE 
The gene encoding ACE is composed of two homologous regions and codes for both a 
somatic and testis isoenzyme. Homozygous mice lacking both ACE isozymes suffer from not 
only low blood pressure, but also severe renal disease. For instance, the renal papilla is 
markedly decreased and the intrarenal arteries exhibit vascular hyperplasia associated with a 
perivascular inflammation. These animals cannot effectively concentrate their urine [148]. 
These manifestations suggest an essential role of ACE in systemic blood pressure, kidney 
development and function, and male fertility [148]. Krege et al [149] also created ACE-
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deficient mice and found that all homozygous female mutants were fertile and males had 
blood pressures that were 15-20 mm Hg less than normal. Interestingly, Gonzalez-Villalobos 
et al [150] created a kidney-specific ACE knockout mouse and showed that the absence of 
intrarenal ACE can protect against hypertension. The absence of kidney ACE substantially 
blunts the hypertension induced by Ang II infusion (a model of high serum Ang II) or by nitric 
oxide synthesis inhibition (a model of low serum Ang II). Furthermore, the renal responses to 
high serum Ang II observed in control mice, such as intrarenal Ang II accumulation, sodium 
and water retention, and activation of ion transporters in the loop of Henle (NKCC2) and distal 
nephron (NCC, ENaC, and pendrin) as well as the transporter activating kinases OSR1 and 
SPAK, were effectively prevented in mice lacking kidney ACE.  
(d) Mice lacking AT1RA and/or AT1RB 
Whereas human possesses a single AT1 receptor, there are two AT1 receptor isoforms in 
rodents (AT1A and AT1B) that are products of separate genes (Agtr1a and Agtr1b). Knockout 
of the AT1A receptor (Agtr1a) gene in mice causes a drop in blood pressure in both 
heterozygotes and homozygotes [151]. Blood pressure can be further reduced in the deficient 
mice, by administration of losartan, suggesting that the AT1B receptor can contribute to blood 
pressure regulation in the absence of AT1A receptor. In the absence of AT1A receptors, the 
AT1B receptor contributes to the regulation of resting blood pressure [152]. 
Mice lacking both receptor subtypes exhibit phenotypes similar to those of mice lacking Agt, 
characterized by marked hypotension, low body weight gain and abnormal kidney morphology 
including delayed maturity in glomerular growth, hypoplastic papilla, renal arterial 
hypertrophy and increased early neonatal death [153].  
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(e) Mice lacking AT2R 
The AT2 receptor targeted by gene deletion (AT2 knockout mice) has been reported by two 
groups in 1995 [154, 155]. Deletion of the AT2 receptor resulted in a significant increase in 
blood pressure and enhanced vascular sensitivity to Ang II in both models. However, AT2-
deficient mice appeared to be normal, and no renal developmental anomalies were described. 
Moreover, these animals have normal GFR and the pressure-natriuresis relationship [156]. 
 
1.6.3.1. 2 Transgenic (Tg) mice overexpressing systemic RAS  
(a) Mice overexpressing renin 
The Ren2 transgene from the 129/Ola strain of mouse was introduced into the genome of the 
rat and the  expression of this gene causes severe hypertension by 8 weeks of age [157].  
However, Tg rats harboring either the human renin gene or the human Agt gene do not 
develop hypertension, because of strict species specificity in the reaction between renin and 
Agt; therefore, human renin  is unable to cleave mouse Agt and vice versa [158]. Thus, double 
human Tg mice were created and became a useful experimental model for studying human-
specific enzyme kinetics and drug development [159]. 
(b) Mice overexpressing Agt 
By injecting the entire rat Agt gene into the germ line of NMRI mice, the resulting Tg animals 
developed hypertension with a mean arterial blood pressure of 158 mm Hg in males and 132 
mmHg in females. Total plasma Agt and plasma Ang II concentrations were about three times 
as high as those of negative control mice [160]. Using targeted gene disruption and 
duplication, the generated mice were genetically identical [(129 x C57BL6) F1] except for 
having one, two or three functional copies of the gene coding for Agt [161, 162]. Plasma 
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steady-state Agt levels increase progressively but not linearly with Agt gene copy number, 
ranging from zero in the zero-copy animals to approximately 145% normal in the four-copy 
animals. Blood pressures increase progressively and significantly with increases in the number 
of functional Agt gene copies, with a change in mean arterial pressure of approximately 8 
mmHg per copy. 
(d) Mice overexpressing AT1 receptor 
 
Le et al [163] created mice with 3 and 4 copies of the Agtr1a gene locus on an inbred 129/Sv 
background. AT1A mRNA expression and AT1-specific binding of Ang II were increased in 
proportion to Agtr1a gene copy number. In female mice, but not in males, there was a highly 
significant positive correlation between blood pressure and AT1A receptor over-expression. 
 
1.6.3.1. 3 Tg mice overexpressing intrarenal RAS 
In additional to systemic RAS transgenic mice, animal models overexpressing intrarenal RAS 
have been generated. Ding et al [164] created Tg mice with human Agt gene specifically 
expressed in the proximal tubular cells of kidney. They employed kidney androgen-regulated 
protein (KAP) promoter to drive the expression of transgene.  
The KAP was originally identified as an abundant 20 KDa polypeptide product derived from 
in vitro translation of mouse kidney RNA. The KAP mRNA represents the most abundant (~ 
4% of the total poly(A) RNA) mRNA species that is induced by androgens in the mouse’s 
kidney [165]. The KAP mRNA exhibited unusual sensitivity to low concentrations of the 
androgen-receptor complex. Using the technique of in situ hybridization with single stranded 
RNA probes, the renal proximal tubular cells were identified as the site of synthesis of KAP 
mRNA [165].  
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enhancer. Therefore, theoretically, replacement of the Agt coding region with any cDNA 
(inserted at the NotI site) should result in a proximal tubule-specific and androgen-regulated 
gene expression [167] (Figure 1-29). 
 
1.6.4 RAS paradox 
The beneficial effects of inhibitors of ACE or AT1R blockade in the prevention of diabetic 
renal disease imply that Ang II is a major mediator of progressive renal injury [168, 169]. 
However, the measurement of the circulating components of the RAS indicates their reduction   
in diabetic animals. [170]. This RAS paradox suggests intrarenal activation of the RAS in DN 
[61]. Several observations have showed that, in spite of normal or suppressed plasma renin 
activity, the intrarenal content of renin is increased. Early STZ-induced diabetes stimulated 
proximal tubule renin mRNA expression in the rat and this process was reversed with insulin 
therapy [171]. Our laboratory also demonstrated that rat IRPTCs stimulated by high-glucose 
expressed higher Agt levels, via PKC signal pathway [172].  
 
1.6.4.1 Hemodynamic effects of Ang II 
Ang II acts on AT1 receptor and exerts vasoconstriction effect. Micropuncture measures in 
rats infused with Ang II showed that it constricts both afferent and efferent arterioles, but has a 
greater effect on efferent arterioles than afferent ones. As a result, Ang II increases glomerular 
pressure [173, 174].  Control of glomerular hypertension by ACE inhibitors in Munich-Wistar 
rats prevented the development of proteinuria and structural lesions [175, 176]. In T2D 
patients with albuminuria, the resistance of efferent arterioles and the glomerular pressure 
were higher than in patients with normoalbuminuria. Treatment with cilazapril decreased 
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glomerular pressure and albuminuria[177]. These findings demonstrated that hemodynamic 
effects of Ang II play an important role in the development of DN. 
 
1.6.4.2 Non-hemodynamic effects of Ang II 
In addition to its hemodynamic effect, Ang II has multiple effects, including inducting 
hypertrophy and proliferation, increasing tubular reabsorption, promoting fibrosis and 
apoptosis. 
Mesangial cell protein synthesis is stimulated by Ang II, with enhanced production of 
extracellular matrix proteins and elaboration of TGF-β1 [178]. In human mesangial cells, Ang 
II stimulated vascular permeability factor/vascular endothelial growth factor production, 
contributing to increased capillary permeability and proteinuria in glomerular diseases [179]. 
In another study, an AT1-receptor antagonist, but not the calcium channel blocker amlodipine, 
normalized the reduced nephrin expression in podocytes from spontaneously hypertensive rats 
with superimposed STZ-induced diabetes, suggesting Ang II in diabetes leads to suppression 
of nephrin protein expression in the podocyte slit diaphragm [180, 181]. 
In our laboratory, we created transgenic mice specifically overexpressing Agt in proximal 
tubular cells, where intrarenal Ang II was overproduced. Ang II overexpression led to tubular 
hypertrophy, tubular fibrosis, albuminuria and tubular apoptosis [182]. 
 
1.6.5 ACE2/ Ang 1-7/MAS axis 
1.6.5.1 ACE2 
Human and rodent ACE2 are similar proteins containing 805 amino acids, which include an 
N-terminal signal sequence, a single active-site catalytic region, and a C-terminal membrane 
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pattern of ACE2 expression is similar to that of mouse kidneys. In kidneys from healthy 
control subjects, Lely et al. [188] found ACE2 expression in tubular, glomerular visceral and 
parietal epithelial cells, and in vascular muscular smooth muscle cells and the endothelium of 
interlobular arteries as well.  
In rat models of hypertension, renal ACE2 mRNA and protein are decreased [189]. Koka et al 
[190] observed low ACE2 levels in human hypertensive kidneys compared with normal 
human kidneys.  Renal expression of ACE2 is downregulated in murine models of diabetes 
and in diabetic patients [187, 191-193]. 
Administration of human recombinant ACE2 to diabetic Akita mice significantly reduced 
albuminuria, associated with decreased blood pressure [194]. Similarly, intravenous 
administration of recombinant adenovirus carrying the mouse ACE2 gene to rats with STZ-
diabetes was associated with diminished albuminuria and glomerulosclerosis, although 
systolic BP was also reduced [195].  Nadarajah et al [196] overexpressed ACE2 in podocytes 
in experimental diabetic nephropathy using Tg methods where a nephrin promoter drove the 
expression of human ACE2. After STZ-induced diabetes, ACE2 Tg mice are protected against 
the early development of albuminuria and show partial preservation of podocyte proteins and 
podocyte number, attenuated glomerular histological injury, and suppressed kidney cortical 
TGF-β1 expression. In 2009, a phase I clinical trial looking at recombinant ACE2 
administration in humans (NCT00886353) was completed, demonstrating that administration 
of rhACE2 was well tolerated by healthy human subjects [197]. 
ACE2-deficient mice are viable as well as fertile, and are characterized by normal cardiac 
function and plasma levels of Ang II [198, 199]. However, baseline blood pressures of ACE2-
deficient mice vary according to genetic strain (Table 1-3). In C57BL/6 mice, ACE2 knockout 
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hypertension present decreased amounts of Ang 1–7 in the urine when compared with healthy 
volunteers [204]. 
In the nonrenal vasculature, Ang 1-7 exerts a vasodilatory effect by increasing the production 
of nitric oxide (NO), prostaglandins or endothelium-dependent hyperpolarizing relaxing factor 
[173, 176, 177]. Sampaio et al. [205] revealed the molecular basis for the NO-releasing 
activity of Ang 1-7. Using human aortic endothelial cells and Chinese hamster ovary cells 
stably transfected with Mas cDNA, they demonstrated that Ang 1-7 stimulates eNOS 
activation and NO production via Akt-dependent pathways. These effects were blocked by the 
Ang 1-7 receptor antagonist A-779, suggesting the involvement of Mas receptor signalling 
pathways. 
Van der Wouden et al [175] studied the effects of Ang 1-7 on the renal vasculature in vitro and 
in vivo. They found that Ang 1-7 alone had no effect on the renal vasculature in any of the 
experiments, but antagonized Ang II in renal vessels in vitro. Ren et al showed that Ang 1-7 
caused afferent arteriole dilatation due to the production of NO [206]. Infusion of Ang 1-7 into 
spontaneously hypertensive rats (SHR) normalizes systolic blood pressure [207]. In Wistar-
Kyoto rats and SHR, Ang 1-7 has a regulatory role in the kidney vasculature including the 
attenuation of the contractile effect of Ang II, which is blocked by antagonism of the Mas 
receptor, cyclo-oxygenase inhibition, or NOS inhibition [208].  
Antidiuretic effects of Ang 1–7 are associated in male Wistar rats with increases in urinary 
Na+ concentration, urinary osmolality, and reduction in creatinine clearance. These effects are 
blocked by administration of A-779 or losartan [209]. In proximal tubular cells, Ang 1-7 
inhibits sodium flux, an effect associated with activation of phospholipase A2 [210] and 
inhibits the ouabain-sensitive Na+/K+-ATPase [211]. 
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have affected the imprinting of the neighboring genes [171, 214]. In 2003, Santos et al. finally 
identified Mas as a functional receptor for Ang 1-7 [169].  
The analysis of the human MAS cDNA sequence revealed an open reading frame that codes 
for a 325-amino-acid protein [213]. The protein consists of seven membrane-spanning α-
helices and hydrophilic N- and C-terminal ends. Mas is highly conserved except in its 
hydrophilic amino-terminal domain, with mouse and rat homologues sharing 97% identity, 
compared with 91% between the mouse and human forms [215]. 
Mas is ubiquitously expressed in many tissues, including kidney, heart, vasculature, brain, 
liver, spleen, testis and lung [215]. Within the kidney, Mas is localized in afferent arterioles, 
and also in proximal tubules, collecting ducts and the thick ascending limb of Henle’s loop. It 
is detected within glomeruli from rat, but not from sheep [215]. In human mesangial cells, 
Mas protein expression has been detected by immunoblot [216]. 
The phenotype of the Mas knockout mouse appears to be highly dependent on strain. Mas-
deficient mice on the mixed 129XC57BL/6 genetic background are healthy, grow normally, 
and show no apparent developmental anomaly [163]. Indeed, these mice are normotensive and 
display normal plasma levels of Ang II [163]. However, Mas knockout mice on a pure 
C57BL/6 genetic background exhibit impaired cardiac function that is partially due to an 
increase in collagen expression to a profibrotic phenotype [166]. In addition, C57BL/6 Mas 
knockout mice exhibit a renal phenotype that is characterized by sodium and water retention, 
glomerular hyperfiltration, microalbuminuria, and renal fibrosis [164]. Mas-deficient mice on 
the FVB/N genetic background display a cardiovascular phenotype that is characterized by 
increased arterial blood pressure, lower eNOS expression, reduced NO production, and 
impaired endothelial function, compared to wild-type mice [217]. In addition, the NADPH 
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oxidase catalytic subunit gp91 (phox) protein is expressed at a higher level in Mas-deficient 
mice compared to wild-type, whereas superoxide dismutase and catalase activities are reduced 
[217].  
 
1.6.6 Clinical trials of RAS blockade in diabetic patients 
RAS system plays a crucial role in the pathophysiology of DN. Clinical trials have established 
the efficacy of ACEi and ARBs in reducing the progression of DN. In addition to a reduction 
in systemic blood pressure, RAS blockade reduces proteinuria, thus slowing progression of 
DN [218]. 
The benefits of an ACEi in T1D diabetes can be demonstrated early in the course of the 
disease when microalbuminuria is the only clinical manifestation. The administration of 
captopril to 235 normotensive T1D patients with microalbuminuria decreased both albumin 
excretion and, at two years, progression to overt diabetic nephropathy when compared with 
patients treated with placebo [219, 220]. This effect is partly independent of its blood 
pressure-lowering effects [220]. A more pronounced benefit was demonstrated in the largest 
trial to date in T1D patients who already had overt nephropathy [221, 222]. Captopril 
treatment was associated with a 50% reduction in the risk of the combined end points of death, 
dialysis and transplantation independent of the small disparity in blood pressure between the 
groups [222].  
In T2D, two major trials, IDNT (Irbesartan in Diabetic Nephropathy Trial) and the RENNAL 
(Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan), compared 
ARBs to placebo and demonstrated that ARBs are effective in reducing proteinuria and the 
incidence of a doubling of the plasma creatinine [223-225]. The ADVANCE trial (the Action 
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in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) 
compared the use of a fixed combination of ACE inhibitor perindopril and the diuretic 
indapamide to placebo in over 11,000 patients with type 2 diabetes [226]. After a mean of 4.3 
years, the patients treated with active therapy had a significant reduction in the rate of new 
onset of microalbuminuria (19.6 versus 23.6 percent) and in the combined endpoint of new 
onset of microalbuminuria, worsening of microalbuminuria, or new onset or worsening of 
macroalbuminuria [227]. 
 
1.7 Animal models of DN 
An ideal animal model would reproduce most or all of the lesions of human DN [228]. In 
2005, the nephropathy subcommittee of the Animal Models of Diabetic Complications 
Consortium (AMDCC) published an account of phenotyping standards, validation criteria, and 
observations about currently available murine strains and models of DN [229].  
STZ is a compound that has a preferential toxicity toward pancreatic β cells because its 
glucose moiety is avidly transported into β cells by GLUT2. After it enters the β cells, STZ 
can damage pancreatic β cells, leading to hypoinsulinemia and hyperglycemia. STZ-treated 
models develop a modest degree of proteinuria and serum creatinine increase, as well as 
minimal mesangial matrix expansion, depending on the genetic background [230]. However, 
interpreting results in this model may be complicated by nonspecific toxicity of STZ. To 
circumvent this potential issue, one may use the insulin-2 Akita (Ins2+/C96Y) mouse mutant 
model of T1D [231]. This point mutation causes misfolding of the insulin protein, toxic injury 
to pancreatic β cells, and impaired capacity to secrete insulin, resulting in T1D [232]. The 
mice are commercially available through the Jackson Laboratories. 
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Table 1-4. Selected mouse models of diabetes studied for DN [229] 
 
Mouse model 
 
Diabetes type 
 
Advantages Disadvantages 
Streptozotocin 
 
Type 1  Well-established, reproducible, 
timed; may be established in 
strains both resistant and 
susceptible to DN 
 
Potential for nonspecific 
toxicity; strain-dependent dosing 
necessary; biohazard:  potential 
mutagen 
Ins2 Akita  Type 1 Commercially available (JAX); 
autosomal dominant mutation 
 
Presently only C57BL/6 
commercially available; 
C57BL/6 relatively resistant to 
nephropathy;  hyperglycemia in 
females is mild 
NOD Type  
 
Type 1  Spontaneous development of β-
cell failure may mimic 
pathophysiology of the disease in 
humans; available commercially 
 
Unpredictable timing of diabetes 
development; no appropriate 
control strain; needs insulin 
therapy to survive long periods; 
multigenetic cause of diabetes 
precludes easy intercrosses 
Db/db 
 
Type 2  
 
 
Available on multiple strains; 
available commercially 
Infertile; autosomal recessive; 
mutation in leptin receptor is a 
very rare cause of obesity and 
T2D in humans 
Ob/ob  
 
Type 2  
 
Exists in diverse inbred strains; 
available commercially 
Infertility-can be circumvented 
with leptin; autosomal recessive; 
nephropathy uncharacterized; 
mutation of leptin is a very rare 
cause of obesity and T2D in 
humans 
High-fat diet  
 
Type 2  
 
Onset can be determined by the 
investigator 
 
Only C57BL/6 reported to be 
susceptible; hyperglycemia not 
prominent 
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The db/db mouse model is currently the most widely used mouse for DN in settings of T2D 
and exhibits many features similar to human DN. The db gene encodes for a G-to-T point 
mutation of the leptin receptor, resulting in abnormal splicing and defective signalling of the 
leptin [233]. The mice become obese around 3 to 4 weeks of age. Elevations of plasma insulin 
begin at 10 to 14 days and of blood sugar at 4 to 8 weeks [234]. After 16 weeks of age, there is 
a very consistent threefold increase in mesangial matrix expansion[235]. DN in these mice is 
characterized by albuminuria, podocyte loss, and mesangial matrix expansion [236]. Another 
T2 DN model, the ob/ob recessive obese mouse carries a mutation in leptin, the ligand for the 
leptin receptor. Renal lesions and function change in C57BL/6J ob/ob mice are said to be 
relatively mild [229]. High-fat diet induced obesity and insulin resistance in C57BL6 mice 
provide a commonly used approach to study T2 DN. However, hyperglycemia is not 
prominent in this model [229] (Table 1-4). 
 
 
1.8 Objectives of the present study  
Rationale: DN is the leading cause of all ESRD in North America [13]. Although there is no 
question that there are changes seen in the glomerulus in patients with DN, it is also generally 
accepted that tubulointerstitial changes are a prominent component of the disease [237]. 
Tubulointerstitial fibrosis and tubular atrophy may be a better predictor of renal disease 
progression than glomerular pathology [238]. 
Activation of RAS plays a critical role in the progression of DN, as can be seen in the 
effectiveness of ACEi and ARB on the DN [168]. The existence of a local intrarenal RAS is 
now well accepted and human and murine RPTCs express all components of the RAS [131, 
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136]. Our laboratory has reported that Tg mice that specifically overexpress Agt, the sole 
precursor of angiotensins in RPTCs, develop hypertension, albuminuria, and tubular apoptosis 
[239, 240]. Furthermore, Agt overexpression enhances tubular apoptosis in STZ-induced 
diabetic mice [182]. These findings indicate that intrarenal RAS activation and hyperglycemia 
act in concert to enhance hypertension and RPTC apoptosis in diabetes. 
Enhanced ROS generation also has been implicated in the progression of DN [241]. Ang II is 
a potent stimulator of ROS production by heightened NADPH oxidase activity in mesangial 
cells and RPTCs [242, 243]. Cat, an antioxidant enzyme, converts H2O2 to water and oxygen 
and thus mitigates the toxic effects of H2O2. To study the mechanism (s) of Ang II action on 
ROS generation and kidney-dependent hypertension, double-transgenic mice specifically 
overexpressing Agt and Cat in their RPTCs were created in our laboratory. Overexpression of 
Cat prevented hypertension and renal injury in the Agt Tg mice [244]. Another animal model, 
db/db catalase Tg mouse, indicated a crucial role for intrarenal ROS in the progression of 
hypertension, albuminuria, interstitial fibrosis, and tubular apoptosis in T2D diabetes [245]. 
Thus, in the diabetic milieu, both glycemia and Ang II can induce ROS generation and these 3 
factors play important roles in the development of hypertension and DN. 
ACE2 shares 40–42% homology in the catalytic domain with ACE, although ACE2 is non-
sensitive to ACEi [128]. ACE2 specifically cleaves Ang II into heptapeptide Ang 1–7, which 
acts on the membrane-bound MasR [169]. Ang 1–7 opposes many Ang II-mediated actions, 
including vasoconstriction, proliferation, hypertrophy and fibrosis [246]. Recently, 
administration of recombinant human ACE2 was demonstrated to attenuate Ang II-dependent 
and pressure overload-induced hypertension and myocardial remodeling as well as renal injury 
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in ACE2 KO mice [247-249], indicating an important counterregulatory role of ACE2 in Ang 
II-induced heart and kidney disease. 
Our laboratory has recently observed that renal ACE2 expression and urinary Ang 1–7 were 
lower in T1D Akita mice and that dual RAS blockade normalizes ACE2 expression, prevents 
hypertension and ameliorates tubular fibrosis and apoptosis in Akita Agt-Tg mice [250]. The 
molecular mechanism(s) by which RAS blockade normalizes renal ACE2 expression, 
however, remains undefined. Furthermore, no one has reported how ROS and Cat regulate 
ACE2 in Akita mice till now. Therefore, the objectives of the present studies are to 
investigate:  
1) Whether oxidative stress is involved in the development of hypertension and nephropathy 
in Akita mice via downregulation of renal ACE2 expression.  
2) Whether Ang 1-7 is involved in the prevention of the development of hypertension and 
kidney injury in diabetic Akita mice. 
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2.1 Abstract 
We investigated the relationship between oxidative stress, hypertension, renal injury and 
angiotensin-converting enzyme-2 (Ace2) expression in type 1 diabetic Akita mice. Blood 
glucose, blood pressure and albuminuria were monitored for up to 5 months in adult male 
Akita and Akita catalase (Cat) transgenic (Tg) mice specifically overexpressing Cat, a key 
antioxidant enzyme in their renal proximal tubular cells (RPTCs). Same-age non-Akita 
littermates and Cat-Tg mice served as controls. In separate studies, adult male Akita mice (14 
weeks) were treated with Ang 1-7 (500 μg/kg-1.day-1, subcutaneously) ± A-779, an antagonist 
of Mas receptor (10 mg/kg-1.day-1) and euthanized at the age of 18 weeks.  The left kidneys 
were processed for histology and apoptosis studies. Renal proximal tubules were isolated from 
the right kidneys to assess protein and gene expression. Urinary angiotensinogen (Agt), 
angiotensin II (Ang II) and Ang 1-7 were quantified by specific ELISAs. Overexpression of 
Cat attenuated renal oxidative stress, prevented hypertension, normalized RPTC Ace2 
expression and urinary Ang 1-7 levels (both were low in Akita mice), ameliorated glomerular 
filtration rate, albuminuria, kidney hypertrophy, tubulointerstitial fibrosis and tubular 
apoptosis, and suppressed profibrotic and proapoptotic gene expression in RPTCs of Akita 
Cat-Tg mice compared with Akita mice.  Furthermore, daily administration of Ang 1-7 
normalized systemic hypertension in Akita mice, which was reversed by A-779. These data 
demonstrate that Cat overexpression prevents hypertension and progression of nephropathy 
and highlight the importance of intrarenal oxidative stress and Ace2 expression contributing to 
hypertension and renal injury in diabetes. 
 
 
 
67 
2.2 Introduction 
Oxidative stress is implicated in the progression of diabetic complications. High glucose 
(HG, 25 mM D-glucose) induces the generation of reactive oxygen species (ROS) that 
contribute to apoptosis in podocytes, mesangial and tubular cells [1-3].  Angiotensin II (Ang 
II) also stimulates ROS generation via heightened nicotinamide-adenine dinucleotide 
phosphate (NADPH) oxidase activity in various kidney cell types, whereas antioxidants 
provide renal protection, in part by ameliorating oxidative stress [4-6]. Taken together, these 
data strongly link oxidative stress, RAS activation and kidney injury to diabetes.  
Human and murine renal proximal tubular cells (RPTCs) express all RAS components 
[7-10]. In the kidneys, angiotensinogen (Agt, the sole substrate of all angiotensins) is 
expressed predominantly in RPTCs and sequentially cleaved by renin and angiotensin 
converting enzyme (ACE) to yield active Ang II. Ang II is then cleaved by angiotensin 
converting enzyme-2 (Ace2) yielding angiotensin 1-7 (Ang 1-7), which has opposing actions 
to Ang II (See recent reviews, references [11, 12]).  
Ace2 shares 40-42% homology with ACE but possesses distinct and different 
biochemical activities [13, 14]. Ace2 specifically cleaves Ang I and Ang II to generate Ang 1-
9 and Ang 1-7, respectively. However, Ace2 is 400-fold more effective cleaving Ang II than 
Ang I, resulting in predominant Ang 1-7 formation [15, 16]. The identification of Mas as a 
receptor for Ang 1-7; genetic deletion of the Mas receptor leads to kidney injury [17], which 
established Ang 1-7 as a part of the RAS cascade. Recombinant human Ace2 administration 
attenuates Ang II-dependent and pressure-overload-induced hypertension, myocardial 
remodeling and renal injury in Ace2 knockout mice [18-20] supporting an important 
counterregulatory role for Ace2 in Ang II-mediated cardiac and renal pathology. 
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We previously examined the role of RAS components in renal injury, reporting for 
example, that transgenic (Tg) mice specifically overexpressing rat Agt in their RPTCs develop 
hypertension, albuminuria and kidney injury [21, 22]  Further, in diabetic mice, hyperglycemia 
and intrarenal Agt overexpression act together to increase hypertension and kidney injury [23]. 
We also recently observed that renal Ace2 expression and urinary Ang 1-7 were lower in type 
1 diabetic Akita mice and that treatment with RAS blockers normalized Ace2 expression and 
prevented hypertension development in these Akita mice [24]. The molecular mechanism(s) 
by which RAS blockade normalizes renal Ace2 expression, however, remains undefined.  
Our present study investigated whether oxidative stress is involved in the development 
of hypertension and nephropathy in Akita mice via down-regulation of renal Ace2 expression.  
We used a cDNA encoding catalase (Cat), an antioxidant enzyme that by converting hydrogen 
peroxide (H2O2) to water and oxygen mitigates the toxic effects of H2O2. In the kidneys, Cat is 
localized to the cytoplasm of RPTCs and is not detectable in other parts of the nephron [25]. 
For these reasons, we created Akita Cat-Tg mice that overexpress rat Cat selectively in their 
RPTCs by cross-breeding heterozygous Akita mice with our established homozygous Tg mice 
overexpressing rat Cat in RPTCs [26]. Here we report that overexpression of Cat in RPTCs of 
Akita mice normalizes renal Ace2 expression and urinary Ang 1-7 levels, prevents 
hypertension, attenuates glomerular filtration rate (GFR), renal hypertrophy, tubulointerstitial 
fibrosis and tubular apoptosis, and suppresses profibrotic and apoptotic gene expression. 
Furthermore, daily administration of Ang 1-7 normalized systemic hypertension in Akita 
mice, which was reversed by the Mas receptor antagonist A-779.  
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2.3 RESEARCH DESIGN AND METHODS 
Chemicals and Constructs 
Ang 1-7 and the mas receptor antagonist, A-779 (d-Ala-7-Ang I/II/1-7) were purchased 
from Bachem (Torrence, CA, USA). The following antibodies were used: bovine Cat 
polyclonal antibody and β-actin monoclonal antibody (Sigma-Aldrich Canada Ltd. ,Oakville, 
ON, Canada), polyclonal anti-heme oxygenase-1 (HO-1) (Assay Designs, Ann Arbor, MI, 
USA), monoclonal anti-collagen type IV antibody (Chemicon International, Temecula, CA, 
USA), polyclonal anti-TIM-1/KIM-1/HAVCR, anti-hLAP/TGFb1 and anti-Ace2 antibody 
(R&D Systems, Minneapolis, MN, USA), polyclonal anti-transforming growth factor-beta 1 
(TGF-β1), monoclonal anti-aquaporin-1 (AQP-1), and anti-ACE antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). A rabbit polyclonal antibody against rAgt was 
generated in our lab (J.S.D.C.) [27].  This antibody is specific for intact rat and mouse Agt (55-
62 kDa) and does not cross-react with pituitary hormone preparations or other rat or mouse 
plasma proteins. pKAP2 plasmid containing the kidney-specific androgen-regulated protein 
(KAP) promoter responsive to testosterone stimulation was a gift from Dr. Curt Sigmund 
(University of Iowa, Iowa, IA, USA) [28]. Oligonucleotides were synthesized by Invitrogen 
(Burlington, ON, Canada). Restriction and modifying enzymes were purchased from 
Invitrogen, Roche Biochemicals (Dorval, QC, Canada) or GE Healthcare Life Sciences (Baie 
d'Urfé, QC, Canada). 
 
Generation of Akita Transgenic Mice Overexpressing Rat Cat  
Tg mice (C57Bl/6 background) that overexpress rat Cat-HA (HA-tag, a sequence 
encoding amino acid residues 98-106 (YPYDVPDYA) of human influenza virus hemagglutinin) 
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in their RPTCs (line #688) driven by the KAP gene promoter were created in our lab 
(J.S.D.C.) and have been described elsewhere [26]. Homozygous Cat-Tg mice were then 
crossed with heterozygous Akita mice (C57BL/6-Ins2Akita/J, Jackson Laboratories, Bar Harbor, 
ME, USA ((http://jaxmice.jax.org); N.B., homozygous Akita mice are infertile). Breeding was 
continued until Akita Cat-Tg mice were obtained. These mice are homozygous for the Cat 
transgene but heterozygous for the insulin2 gene mutation. The presence of the Cat-HA 
transgene in the Akita Cat-Tg mouse was confirmed by PCR of genomic DNA with specific 
primers against the Cat-HA transgene [26] and the mutated insulin2 gene [24, 29]. The 
mutation in the insulin2 gene was identified by Fnu4H1 digestion (1 h at 37°C) of the PCR 
product revealing two fragments (280 bp and 140 bp) separated on 3% agarose gel 
electrophoresis.  
 
Physiological Studies 
Male adult non-Akita littermates, Akita, Cat-Tg and Akita Cat-Tg mice (8 mice per 
group) were studied. All animals had ad libitum access to standard mouse chow and water. 
Animal care and procedures were approved by the CRCHUM’s Animal Care Committee. 
Systolic blood pressure (SBP) was monitored in the morning with a BP-2000 tail-cuff 
pressure monitor (Visitech Systems, Apex, NC, USA) at least 2-3 times per week per animal, 
for 12 weeks [21-24]. The mice were habituated to the procedure for at least 15-20 min per 
day for 5 days before the first SBP measurements. SBP values are expressed as the mean ± 
SEM. All animals were housed individually in metabolic cages for 24 h prior to euthanasia at 
the age of 20 weeks. Body weight was recorded. Urine was collected and assayed for albumin 
and creatinine by ELISAs (Albuwell and Creatinine Companion, Exocell, Inc., Philadelphia, 
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PA, USA) [21-24]. Immediately following euthanasia, the kidneys were removed, 
decapsulated and weighed. The left kidneys were processed for histology and immunostaining, 
and the right kidneys were harvested for isolation of renal proximal tubules (RPTs) by Percoll 
gradient [21-24]. 
In separate studies, adult male Akita mice (age 14 weeks) were treated subcutaneously 
with Ang 1-7 (500 μg/kg-1.day-1) ± A-779 (10 mg/kg-1.day-1) and euthanized at age 18 weeks 
(6 mice per group). Controls were untreated non-Akita WT. SBP was measured thrice weekly 
[21-24]. 
The glomerular filtration rate (GFR) was estimated as described by Qi et al. [30], as 
recommended by the Animal Models of Diabetic Complications (AMDCC) 
(http://www.diacomp.org/) with slight modifications [31]. 
 
Agt, Ang 1-7 and Ang II Measurement  
Mouse urinary Agt levels were assayed by ELISA (Immuno-Biological Laboratories, 
IBL America. Minneapolis, MN, USA) and normalized by urinary creatinine levels.  Serum 
and urinary Ang II and Ang 1-7 levels were assayed by specific ELISAs for Ang II and Ang 1-
7, respectively,  following extraction with a kit (Bachem Americas Inc) [24, 32].  
 
Histology  
Kidney sections (4-5 sections, 3-4 μm thick, per kidney) from 8 animals per group were 
stained with PAS or Masson’s trichrome, and assessed by light microscopy by two 
independent blinded observers. The collected images were analyzed and quantified using the 
NIH ImageJ software (http://rsb.info.nih.gov/ij/)[22-24, 32].  
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Mean glomerular volume on 30 random glomerular sections per mouse was assessed by 
the Weibel method [33] with Motics Images Plus 2.0 image analysis software (Motic 
Instrument, Richmond, BC, Canada) [22-24, 32]. Tubular luminal areas were measured on 
renal sections (6 animals/ group; 4 to 5 sections per kidney, 4 random fields per section, 10 
tubules around the glomerulus per field) with Motics Image Plus 2.0 image analysis software 
[22-24, 32]. Outer cortical RPTs with similar cross-sectional views and clear nuclear structure 
were selected. Mean cell volume was estimated by the Nucleator method [34], as described 
previously [22-24, 32].  
Immunohistochemical staining was performed according to the standard avidin-biotin-
peroxidase complex method (ABC Staining System, Santa Cruz Biotechnologies, Santa Cruz, 
CA, USA) [21-24, 32]. Immunostaining with non-immune normal rabbit serum in non-Akita 
mouse kidneys served as controls and no immunostaining was observed (photographs not 
shown). Oxidative stress in RPTs in vivo was assessed by dihydroethidium (DHE; Sigma) 
staining in frozen kidney sections [35]. In this assay, the nonfluorescent DHE is oxidized to 
fluorescent ethidium by superoxide anion (O2·-). The results were confirmed by standard 
immunohistochemical staining for heme oxygenase 1 (HO-1, an oxidative stress-inducible 
gene that confers cellular oxidative stress in vivo) [32, 36].  The percentage of apoptotic 
RPTCs was estimated semiquantitatively [22-24, 32] by the TUNEL assay (Roche 
Diagnostics, Laval, QC).  
  
Real Time-Quantitative Polymerase Chain Reaction (RT-qPCR) Assays for Gene 
Expression 
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Agt, Ace2, ACE, TGF-β1, collagen type IV and β-actin mRNA expression in RPTs was 
quantified by RT-qPCR with forward and reverse primers as described previously [24, 32].  
 
Western Blotting for Estimation of Protein Expression  
Western blotting for Ace2, ACE and Agt was performed with RPT lysates [24, 32]. The 
membranes were first blotted with anti-Ace2, ACE or Agt antibodies and then re-blotted with 
anti-β-actin monoclonal antibodies and chemiluminescent developing reagent (Roche 
Biochemicals, Inc.). The relative densities of Ace2, ACE, Agt and β-actin bands were 
quantified by computerized laser densitometry (ImageQuant software (version 5.1), Molecular 
Dynamics, Sunnyvale, CA, USA).  
 
Statistical Analysis 
Statistical significance between experimental groups was analyzed by Student’s t-test or 
1-way ANOVA and the Bonferroni correction as appropriate. Data are expressed as mean ± 
SEM. p<0.05 was considered to be statistically significant. 
 
2.4 Results 
RPTC-specific Expression of the Cat Transgene in Akita and Tg Mouse Kidneys  
We confirmed the presence of the mutated insulin2 gene in the RPTs of Akita and Akita 
Cat-Tg mice but not in wild-type (WT) non-Akita or Cat-Tg mice (Figure 1A, a). Likewise, 
the Cat-HA transgene was expressed only in RPTs of Cat-Tg and Akita Cat-Tg mice but not in 
RPTs of WT and Akita mice (Figure 1A, b). Cat levels were significantly higher in RPTCs in 
Cat-Tg mice (Figure 1B, b) and Akita Cat-Tg mice (Figure 1B, d) than in non-Akita WT mice 
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(Figure 1B, a) or in Akita mice (Figure 1B, c). The Cat expression was RPTC-specific and it 
co-localized to aquaporin-1-positive immunostained RPTCs (Figure 1C). HO-1 
immunostaining and DHE staining demonstrated lower levels of oxidative stress in RPTCs of 
Cat-Tg (b in Figures 1D and 1E) than in non-Akita WT mice (a in Figures 1D and 1E). Akita 
mice (c in Figures 1D and 1E) exhibited significantly higher oxidative stress and normalized 
in Akita Cat-Tg mice (d in Figures 1D and 1E). Quantitation of DHE staining confirmed these 
findings (Figure 1F). These results confirm that the KAP gene promoter directs Cat transgene 
expression in the RPTCs of Cat-Tg and Akita Cat-Tg mice and that Cat expression effectively 
attenuates ROS production. 
 
Physiological Parameters in Akita and Tg Mice 
We detected significant differences in SBP between Akita and non-Akita WT mice as 
early as 8 weeks of age. These differences increased with age (from week 14 until week 20; 
Figure 2A). There were no significant differences in SBP between the Akita mouse and Akita 
Cat-Tg mouse until week 16 (Figure 2A). Overexpression of the Cat transgene protected the 
Akita Cat-Tg mouse against increased SBP as compared to Akita mice.  SBP did not differ 
significantly in Cat-Tg mice and non-Akita WT mice (over time) and at 20 weeks (Table I).  
Interestingly, at 20 weeks Akita mice had higher GFR (Figure 2B), urinary Agt (Figure 
2C) and Ang II levels (Figure 2D) and lower Ang 1-7 levels (Figure 2E) than non-Akita mice 
or Cat-Tg mice. Overexpressing Cat attenuated elevated GFR, urinary Agt and Ang II levels 
and normalized Ang 1-7 levels in Akita Cat-Tg mice (Figures 2B, 2C, 2D and 2E, 
respectively). In contrast, serum Ang II levels did not differ significantly among the groups 
studied (Figure 2F). 
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Blood glucose level was significantly higher in Akita and Akita Cat-Tg mice at 20 
weeks than in non-Akita WT or Cat-Tg mice, respectively (Table I). Akita mice also 
exhibited elevated kidney to body weight ratio and heart to body weight ratio at the end of the 
experiment as compared to non-Akita WT controls or Cat-Tg mice (Table I). Cat 
overexpression markedly attenuated, though not completely normalized, these ratios in Akita 
Cat-Tg mice. Urinary albumin/creatinine ratio (ACR) at 20 weeks was significantly higher in 
Akita mice than in non-Akita WT controls or Cat-Tg mice (Table I). Cat overexpression 
partially reduced the ACR in Akita Cat-Tg mice but did not completely normalize it to WT 
control levels. These findings indicate that Cat overexpression effectively attenuate kidney and 
heart hypertrophy and albuminuria without exerting an anti-hyperglycemic effect in the Akita 
Cat-Tg mice.  
 
 
Agt , Ace2 and ACE Expression in Akita and Tg Kidneys 
We noted higher Agt immunostaining in RPTCs of WT controls (Figure 3A, a) relative 
to Cat-Tg mice (Figure 3A, b). Agt immunostaining was significantly increased in Akita mice 
(Figure 3A, c) as compared to WT controls and Cat-Tg mice and normalized in Akita Cat-Tg 
mice (Figure 3A, d). Expression of Ace2 in the RPTCs of WT non-Akita controls (Figure 3B, 
a) or Cat-Tg mice (Figure 3B, b) was also significantly higher as compared to Akita mice 
(Figure 3B, c). Overexpression of Cat normalized Ace2 immunostaining in RPTCs of Akita 
Cat-Tg mice (Figure 3B, d). In contrast, the RPTCs of WT controls (Figure 3C, a) or Cat-Tg 
mice (Figure 3C, b) exhibited decreased staining for ACE relative to Akita mice (Figure 3C, 
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c).  Overexpressing Cat decreased the level of immunostaining for ACE in the RPTCs of Akita 
Cat-Tg mice (Figure 3C, d) vs. Akita mice (Figure 3C, c).  
We confirmed these findings by immunoblotting for Agt, Ace2 and ACE (Figures 3 D-
F,) and by detecting Agt mRNA, Ace2 mRNA and ACE mRNA expression (Figures 3G-I,) in 
isolated RPTCs by RT-qPCR.  
 
Histology at 20 Weeks 
Unlike WT non-Akita mice and Cat-Tg mice, Akita mice exhibited renal structural 
damage (Figure 4A). Histologic findings included tubular luminal dilation and accumulation 
of cell debris in the tubular lumen. Some RPTCs were flattened. Remarkably, overexpression 
of Cat in the Akita Cat-Tg mice markedly suppressed, but did not completely prevent these 
abnormalities. We observed significantly enlarged tubular luminal area, increased glomerular 
tuft and RPTC volume in Akita mice compared to non-Akita WT or Cat-Tg mice (Table I). 
Overexpression of the Cat transgene partially reduced tubular luminal area and glomerular tuft 
volume, and completely normalized RPTC volume in Akita Cat-Tg mice.  
 
Tubulointerstitial Fibrosis and Profibrotic Gene Expression in Akita and Tg Kidneys  
We assessed expression of collagenous components with Masson's trichrome staining, 
and by immunostaining for collagen type IV or TGF-β1. Kidneys from non-Akita WT (a in 
Figures 4B, 4D and 4E) or Cat-Tg mice (b in Figures 4B, 4D and 4E) exhibited significantly 
lower expression of collagenous components, collagen type IV and TGF-β1 relative to Akita 
mice (c in respective Figure 4B, 4D and 4E). Cat overexpression markedly reduced 
tubulointerstitial fibrosis (d in Figures 4B, 4D and 4E) as demonstrated by quantitative 
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analysis of Masson’s  trichrome staining (Figure 4C) and immunostaining for collagen IV 
(Figure 4F) and TGF-β1 (Figure 4G). Quantitation of collagen IV (Figure 4H) and TGF-β1 
mRNA (Figure 4I) expression further confirmed these findings. Collectively, these data 
indicate that Cat overexpression effectively prevents tubulointerstitial fibrosis in Akita Cat-Tg 
mice. 
 
Tubular Apoptosis in Akita and Tg Kidneys 
Next we investigated the impact of Cat overexpression on tubular apoptosis in Akita 
mice by the TUNEL assay. The number of TUNEL-positive nuclei in RPTCs of non-Akita 
WT mice (Figure 5A, a) or Cat-Tg mice (Figure 5A, b) were significantly lower than in 
Akita mice (Figure 5A, c). Cat overexpression significantly reduced the number of TUNEL-
positive cells in Akita Cat-Tg mice (Figure 5A, d) and this was confirmed by semi-
quantitation (Figure 5B).  Consistently, expression of active (cleaved) caspase-3 was also 
lower in non-Akita WT (Figure 5C, a) and Cat-Tg mice (Figure 5C, b) but was higher in 
RPTCs of Akita mice (Figure 5C, c). Cat overexpression attenuated expression of active 
caspase-3 in Akita Cat-Tg mice (Figure 5C, d). Caspase-3 activity assays in isolated RPTs 
confirmed these findings (Figure 5D). 
Akita mice also exhibited increased expression of Bax and Bcl-2 mRNA (Figure 5E) 
and decreased expression of Bcl-xl mRNA (Figure 5F) as compared with non-Akita WT mice 
or Cat-Tg mice.  mRNA expression was normalized in Akita Cat-Tg mice (Figures 5E and 
5F).  
 
Effect of Ang 1-7 Administration on SBP in Akita mice 
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Mean SBP was significantly higher in Akita mice at 13 weeks of age than in WT mice 
(Figure 6A) and remained higher for the duration of the study. Daily administration of Ang 1-
7 for 4 weeks normalized SBP in Akita mice. Co-administration of Ang 1-7 with A-779 
resulted in increases in SBP (Figures 6A and 6B).  
 
 
2.5 Discussion 
Our study demonstrates that Cat overexpression in RPTCs of Akita mice effectively 
attenuates oxidative stress, prevents systemic hypertension and renal injury, normalizes Ace2 
expression in RPTCs, and suppresses Agt, pro-fibrotic and pro-apoptotic gene expression. Our 
observations indicate that ROS level in RPTC plays a critical role in regulating renal Agt gene 
expression and RAS activation and subsequently SBP and kidney injury in vivo. 
Expanding our previous findings that overexpression of Cat in RPTCs prevents 
hypertension and attenuates tubulointerstitial fibrosis and RPTC apoptosis in non-diabetic 
Agt/Cat-Tg mice and type 2 diabetic db/db Cat-Tg mice [32, 37], here we demonstrate  that 
overexpression of Cat also enhances renal Ace2 expression and Ang 1-7 formation.  
Administration of Ang 1-7 prevents systemic hypertension in Akita mice, indicating that 
intrarenal Ang 1-7 formation is critical in counteracting Ang II actions in Akita mice.  These 
findings highlight an important role for intrarenal Ace2 expression and Ang 1-7 formation in 
preventing development of hypertension and nephropathy in diabetic mice.  
The Akita mouse,  an autosomal dominant model of spontaneous type 1 diabetes in 
which the insulin gene2 is mutated, have decreased numbers of β-cells of the pancreatic islets 
and develop hyperglycemia at age of 3-4 weeks [29]. By the age of 30 weeks, male Akita mice 
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manifest impaired renal function and increased oxidative stress markers in their RPTs [38] and 
elevated kidney/body weight and heart/body weight ratios, closely resembling those observed 
in patients with type 1 diabetes.  
Our data indicate that mitigating oxidative stress via kidney-specific overexpression of 
Cat protects diabetes-prone Akita mice against hypertension. The mechanisms underlying 
elevated SBP in Akita mice are largely unknown. The possibility that down-regulation of 
Ace2 gene expression and consequently high Ang II/Ang 1-7 ratio facilitates the development 
of hypertension has received considerable attention [11, 12]. Indeed, our present findings 
demonstrate significantly lower Ace2 and urinary Ang 1-7 and higher ACE, urinary Agt and 
Ang II levels in Akita mice than in non-Akita WT or Cat-Tg mice. Cat overexpression in 
RPTCs normalized these changes. These observations are consistent with our previous 
findings of markedly elevated ACE and depressed Ace2 expression in the kidneys of Agt-Tg 
mice [32] as well as with studies on normotensive Lewis rats, which showed that RAS 
blockade increases cortical Ace2 activity and urinary Ang 1-7 excretion [39]. Normal human 
kidneys express low levels of ACE and high levels of Ace2, and this ratio is reversed in 
kidneys of hypertensive and diabetic patients [40-42]. Furthermore, Ang II was found to up-
regulate ACE and down-regulate Ace2 expression in HK2 cells in vitro [40]. Taken together, 
these findings lend support to the concept that intrarenal RAS activation up-regulates ACE 
activity and down-regulates Ace2 expression via enhanced oxidative stress in RPTCs, 
ultimately contributing to development of hypertension.  
As expected [24], we detected renal structural damage in Akita mice, including tubular 
luminal dilation, glomerular hypertrophy and increased RPTC volume.  Increases in tubular 
lumen in Akita mice would indicate enhanced susceptibility of RPTCs to atrophy [43]. 
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Furthermore, occurrence of RPTC injury in Akita mouse kidneys was supported by augmented 
immunostaining for KIM-1, a molecular marker of RPTC injury [44] (Unpublished results). 
Importantly, selective overexpression of Cat in RPTCs markedly attenuated these 
morphological changes. Thus, hyperglycemia and RAS activation induce kidney damage in 
diabetes, which could be attenuated by Cat overexpression-mediated inhibition of RAS 
activation and action.  
Since glomerular hyperfiltration and microalbuminuria are early clinical markers of 
hypertension- or diabetes-induced nephropathy, we monitored GFR and urinary albuminuria 
and detected enhanced GFR and microalbuminuria in Akita mice at the age of 20 weeks. Cat 
overexpression significantly reduced, though not completely prevented these changes. These 
observations imply a link between intrarenal oxidative stress, RAS activation, GFR and 
albuminuria. However, the underlying molecular mechanism(s) remain large unknown. One 
possible mechanism is that increased intrarenal Ang 1-7 formation and decreased Ang II 
formation in Akita Cat-Tg mice would prevent or attenuate the actions of Ang II on efferent 
arterioles, thereby reducing the glomerular pressure (hyperfiltration), glomerular volume and 
eventually SBP.  Increased urinary Ang 1-7 and reduced Ang II levels in Akita Cat-Tg mice 
lend support to this notion.   
Treatment with Ang 1-7 prevented systemic hypertension in Akita mice, and this can be 
reversed by A-779. These findings are consistent with attenuation by recombinant human 
Ace2 of Ang II-dependent and pressure-overload-induced hypertension in Ace2 knockout 
mice [18-20], supporting an important counterregulatory role for Ang 1-7 in Ang II-mediated 
cardiac and renal abnormalities. 
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We observed modest thickening of the tubular basement membrane in Akita mice, which 
can be prevented by Cat overexpression.  The mechanism by which oxidative stress leads to 
interstitial fibrosis in Akita mice remains unclear. One possibility is that augmented Agt and 
Ang II expression via ROS generation stimulates TGF-β1, subsequently enhancing the 
expression of extracellular matrix proteins, collagen type IV, profibrotic and pro-apoptotic 
proteins in RPTCs, with resultant apoptosis and, ultimately interstitial fibrosis [45]. Indeed, 
neutralizing TGF-β alleviates fibrosis and tubular cell apoptosis in animal models of diabetes 
[46]. Our present study shows higher Agt, TGF-β1 and collagen IV expression and lower 
LAP/TGF-β1 expression (a marker of the inactive TGF-β1 complex) [47] (Unpublished 
results) in RPTs of Akita mice than in non-Akita mice. These changes were mitigated in Akita 
Cat-Tg mice, linking intrarenal oxidative stress to interstitial fibrosis.  
Confirming our previous findings in the kidneys of non-diabetic Agt-Tg, diabetic Agt-
Tg and Akita mice [22-24, 32], we detected more apoptotic RPTCs in Akita mice, shown by 
increased percentage of TUNEL-positive RPTCs parallel with increased active caspase-3 
immunostaining and Bax mRNA expression and decreased Bcl-xL mRNA expression. An 
elevated Bax/Bcl-xL ratio is consistent with induction of tubular apoptosis in Akita mice. 
Once again, these changes were mitigated in Akita Cat-Tg mice. 
Our results may be clinically relevant for type 1 diabetes. Tubulointerstitial fibrosis and 
tubular apoptosis occur in human type 1 diabetic kidneys [48], and tubular atrophy appears to 
be a better indicator of disease progression than glomerular pathology [49]; we suggest that 
tubulointerstitial fibrosis and RPTC apoptosis may be initial events leading to tubular atrophy 
in diabetes. Oxidative stress-mediated decrease of Ace2 gene expression would further 
accelerate this process.  
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In summary, our data indicate a critical role for tubular oxidative stress in the 
development of hypertension, albuminuria, tubulointerstitial fibrosis and RPTC apoptosis in 
Akita mice.  
 
 
 ABBREVIATIONS 
 
Ace2, angiotensin-converting enzyme-2; ACE, angiotensin-converting enzyme; ACR, 
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rAgt, rat angiotensinogen; RAS, renin-angiotensin system; RPTs, renal proximal tubules; 
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2.8 Legends and Figures 
 
Table 2-1.  Physiological Measurements 
 
 WT CAT-Tg Akita Akita CAT-Tg 
(A) Blood glucose 
(mmol/L) 
10.84±0.65 11.16±0.68 34.50±0.72*** 35.10±0.79*** 
(B) Systolic Blood 
Pressure (mmHg) 
108.6±2.56 105.5±1.47 136.7±2.6*** 113.25±5.48††† 
(B) Body Weight (g) 34.46±0.80 34.80±0.39 26.71±0.63*** 26.99±0.60*** 
(C) Kidney Weight  (g) 0.40±0.011 0.41±0.011 0.63±0.022*** 0.53±0.019***,†† 
(D) Heart Weight (g) 0.151±0.007 0.159±0.006 0.173±0.012 0.171±0.011 
(E) Kidney/Body 
Weight ratio (g/g) 
0.0118 
±0.000507 
0.0119 
±0.000361 
0.0234 
±0.000595*** 
0.0201 
±0.000543***,††† 
(F) Heart/Body Weight 
ratio (g/g) 
0.0044 
±0.000117 
0.0046 
±0.000168 
0.0071 
±0.000441*** 
0.0058 
±0.00023**,† 
(G) Albumin/Creatinine 
ratio (μg/ml/mg/dL) 
0.244 
±0.027 
0.174 
±0.026 
4.462 
±1.361*** 
2.15 
±0.553†† 
(H) Glomerular tuft 
volume (X 103 μm3) 
129.7 
±3.99 
137.0 
±5.20 
260.7 
±16.52*** 
180.3 
±9.57***,††† 
(I) RPTC volume 
(X 103 μm3) 
5.44±0.11 4.82±0.05** 9.68±0.26*** 5.86±0.14††† 
(J) Tubular luminal 
Area (μm2) 
51.38±5.37 48.76±5.54 105.7±14.55** 66.27±9.11*,†† 
 
*P<0.05, **P<0.01 and ***P<0.005 vs WT   
†P<0.05, ††P<0.01 and †††P<0.005 vs Akita 
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Figure 2-1: Generation of Akita Cat-Tg mice. (A) (a) Genotyping of the insulin2 mutation in 
non-Akita and Akita mice. (b) Cat-HA transgene expression. PCR analysis of Cat-HA 
transgene in offspring of Cat-Tg line 688 cross-bred with heterozygous Akita mice. Akita Cat-
Tg mice displaying Cat-HA transgene were used in subsequent experiments. 
Immunohistochemical staining for Cat (B) in male non-Akita WT, Akita, Cat-Tg and Akita 
Cat-Tg mouse kidneys by employing rabbit anti-bovine Cat polyclonal antibody. 
Magnification X 600. (C) Co-localization of immunostaining of Cat and Aquaporine-1 (AQP-
1) in male non-Akita WT and Cat-Tg mouse kidneys. Magnification X 200. (D) 
Immunostaining of HO-1 in male non-Akita WT, Akita, Cat-Tg and Akita Cat-Tg mouse 
kidney by employing HO-1 polyclonal antibody. Magnification X 600. (E) Dihydroethidium 
(DHE) (red) staining in mouse kidneys. Magnification X 200. (F) Semi-quantification of DHE 
fluorescence in mouse kidneys. Values are expressed as means ± SEM, N=8 per group. 
**p<0.01. (a) Non-Akita WT mouse. (b) Cat-Tg mouse. (c) Akita mouse. (d) Akita Cat-Tg 
mouse.   
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Figure 2-2: Effect of overexpression of Cat in RPTCs on systolic blood pressure (SBP), 
glomerular filtration rate (GFR), urinary Agt, Ang II and Ang 1-7 levels and serum Ang II 
level in Akita mice.  (A) Longitudinal changes in mean SBP in male non-Akita WT (∆), Cat-
Tg (∇), Akita (▲),and Akita Cat-Tg (▼). Baseline SBP was measured daily over a 5-day 
period before initiation of measurement. (B) GFR, urinary levels of Agt (C), Ang II (d) and 
Ang 1-7 (E) and serum levels of Ang II (F) were measured at the age of week 20 in non-Akita 
WT, Cat-Tg, Akita and Akita Cat-Tg mice. Values are expressed as means ± SEM, N=8 per 
group. *p<0.05; **p<0.01; ***p<0.005; N.S., non-significant. 
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Figure 2-3: Agt, Ace2 and ACE expression in mouse kidneys at the age of week 20. Agt (A), 
Ace2 (B) and ACE (C) immunostaining: a, Non-Akita WT control littermate; b, Cat-Tg 
mouse; c, Akita mouse; d, Akita Cat-Tg mouse. Magnification X 600. Western blotting of Agt 
(D), Ace2 (E) and ACE (F) in mouse RPTs. The membranes were re-blotted for β-actin. Agt, 
Ace2 and ACE levels were normalized by corresponding β-actin levels. Values are expressed 
as means ± SEM (n=8). *p<0.05; **p<0.01; N.S., non-significant. RT-qPCR of Agt (G), Ace2 
(H) and ACE (I) mRNAs in mouse RPTs. Ace2, ACE and β-actin mRNAs were run 
simultaneously in the assays. Agt, Ace2 and ACE mRNA levels were normalized by 
corresponding β-actin mRNA levels. mRNA levels in non-Akita control littermates were 
considered as 100%. Values are expressed as means ± SEM, (n=8) *p<0.05; **p<0.01; N.S., 
non-significant.  
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Figure 2-4: PAS staining, Masson’s trichrome staining, collagen IV and TGF-β1 expression in 
mouse kidneys at the age of week 20. (A) PAS staining. (B) Masson’s trichrome staining. (C) 
Quantification of extracellular matrix component accumulation (Masson’s trichrome staining). 
(D) Immunostaining for collagen IV. (E) Immunostaining for TGF-β1. a, Non-Akita WT 
control littermate; b, Cat-Tg mouse; c, Akita mouse; d, Akita Cat-Tg mouse. Magnification X 
600. (F) Quantitation of immunoreactive collagen IV deposition. (G) Quantitation of TGF-β1 
immunostaining. RT-qPCR of collagen IV (H) and TGF-β1 (I) mRNA.  Values are expressed 
as means ± SEM (n=8)  **p<0.01; N.S., non-significant.  
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Figure 2-5: Apoptosis in mouse kidneys at the age of week 20. (A) TUNEL (green) staining. 
Magnification X 200. Arrows indicate apoptotic cells in proximal tubules. (B) Semi-
quantitation of apoptotic RPTCs in mouse kidneys. (C) Immunostaining for cleaved (active) 
caspase-3 and (D) Caspase-3 activity in isolated RPTs. a, non-Akita WT control littermate; b, 
Cat-Tg mice; c, Akita mouse; d, Akita Cat-Tg mouse. Magnification X 200. RT-qPCR for Bax 
(E) and Bcl-xL (F) mRNA. Bax, Bcl-xL and β-actin mRNAs were run simultaneously in the 
assays. Bax and Bcl-xL mRNA levels were normalized by corresponding β-actin mRNA 
levels. mRNA levels in non-Akita control littermates were considered as 100%. Values are 
expressed as means ± SEM, (n=8) *p<0.05; **p<0.01; ***p<0.005; N.S., non-significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
98 
(A)
(B)
13 14 15 16 17 18
100
110
120
130
140
150
Treatment
    start
**
*** ***
++
***
+++ ++
***
Age (weeks)
Sy
st
ol
ic
 B
lo
od
 P
re
ss
ur
e
(m
m
H
g)
50
75
100
125
150 *** ***
N.S.
**
WT Akita Akita Akita
Ang 1-7
+
Ang 1-7
+
A779
+
N.S.
Sy
st
ol
ic
 B
lo
od
 P
re
ss
ur
e
(m
m
Hg
)
 
 
 
99 
 
Figure 2-6: Effect of Ang 1-7 with or without A-779 on SBP in Akita mice. (A) Longitudinal 
changes in mean SBP in male non-Akita WT mice (∆), Akita mice (▲), Akita mice treated 
with Ang 1-7 (∇), and Akita mice treated with  Ang 1-7 and A-779 (▼). Baseline SBP was 
measured daily over a 5-day period before initiation of treatment. (B) Cross-sectional analysis 
of SBP (measured 2 to 3 times per animal per week in the morning without fasting, at the age 
of week 18 in non-Akita WT mice, Akita mice, Akita mice treated with Ang 1-7 and Akita 
mice treated with Ang 1-7 and A-779. Values are expressed as means ± SEM, (n=6 per 
group). *p<0.05; **p<0.01; ***p<0.005; N.S., non-significant. 
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 3.1 Abstract 
We investigated the relation between Ang 1-7 action, systolic hypertension (sHTN), oxidative 
stress, kidney injury, angiotensin converting enzyme-2 (Ace2) and angiotensin 1-7 receptor 
(MasR) expression in type 1 diabetic Akita mice. Ang 1-7 was administered daily (500 μg/kg 
body weight (BW)/day, subcutaneously) to male Akita mice from 14 weeks of age with or 
without co-administration of an antagonist of the MasR, A779 (10 mg/kg BW/day). The 
animals were euthanized at 20 weeks of age.  Age-matched wild type (WT) mice served as 
controls. Ang 1-7 administration prevented sHTN and attenuated kidney injury (reduced 
urinary albumin/creatinine ratio, glomerular hyperfiltration, renal hypertrophy and fibrosis, 
and tubular apoptosis) without affecting blood glucose levels in Akita mice. Ang 1-7 also 
attenuated renal oxidative stress and the expression of oxidative stress-inducible proteins 
(NADPH oxidase 4, nuclear factor erythroid 2-related factor 2, heme oxygenase 1), pro-
hypertensive proteins (angiotensinogen, angiotensin converting enzyme, sodium/hydrogen 
exchanger-3) and profibrotic proteins (transforming growth factor-beta 1 and collagen IV), 
and increased the expression of anti-hypertensive proteins (angiotensin-converting enzyme 2 
(Ace2) and MasR) in Akita mouse kidneys. These effects were reversed by A779. Our data 
suggest that Ang 1-7 plays a protective role in sHTN and RPTC injury in diabetes, at least in 
part, through decreasing renal oxidative stress-mediated signaling and normalizing Ace2 and 
MasR expression. 
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3.2 Introduction 
Angiotensin-converting enzyme 2 (Ace2), an enzyme homologue of angiotensin-
converting enzyme (ACE), was identified by 2 independent groups in 2000 [1, 2]. Ace2 is 
42% homologous to ACE in the catalytic domain and specifically cleaves angiotensin I (Ang 
I) and Ang II into Ang 1-9 and Ang 1-7, respectively. However, the catalytic efficiency of 
Ace2 on Ang II is 400-fold greater than on Ang I, resulting in direct Ang 1-7 formation [3, 4]. 
Evidence now supports a counter-regulatory role for Ang 1-7  via its own receptor, the Ang 1-
7 receptor or MasR, which  oppose many Ang II subtype 1 receptor (AT1-R)-mediated 
outcomes (for recent reviews, see [5-7]). 
Earlier studies on the effects of Ang 1-7 on hypertension, cardiovascular and renal 
function in hypertensive rats with or without diabetes yielded contradictory results. For 
instance, Giani et al. [8] reported Ang 1-7 attenuation of systolic blood pressure (SBP) and 
reduction in renal oxidative stress and inflammatory markers in Zucker rats. Benter’s group [9, 
10] reported decreased SBP by Ang 1-7 in spontaneously hypertensive rats (SHR) but not in 
streptozotocin-induced diabetic SHR despite amelioration of albuminuria and renal vascular 
dysfunction. In contrast, Tan et al. [11] found no significant reductions in SBP in response to 
Ang 1-7 in SHR and Wistar-Kyoto rats.  
We have established that high glucose induces reactive oxygen species (ROS) 
generation and stimulates angiotensinogen (Agt, the sole precursor of angiotensins) gene 
expression in renal proximal tubular cells (RPTCs) in vitro [12, 13]. Transgenic (Tg) mice 
specifically overexpressing rat Agt in their RPTCs develop hypertension, albuminuria and 
kidney injury [14, 15]. Hyperglycemia and Agt overexpression act in concert to elicit systolic 
hypertension (sHTN) and RPTC apoptosis in diabetic Agt-Tg mice [16]. More recently, we 
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documented that renin-angiotensin system (RAS) blockade and catalase (Cat) overexpression 
in RPTCs prevent sHTN and tubular ROS generation, suppress RPTC apoptosis and normalize 
Ace2 expression in RPTCs of diabetic Akita Agt-Tg [17] and Akita Cat-Tg mice [18], 
supporting the view that enhanced ROS generation and RAS activation are pivotal in down-
regulation of Ace2 expression and renal injury in diabetes.  
In the present study, we have investigated the impact of Ang 1-7 on sHTN, oxidative 
stress and kidney injury in diabetic Akita mice. Here, we report that Ang 1-7 administration 
prevented sHTN and renal oxidative stress, attenuated glomerular hyperfiltration, albuminuria, 
renal hypertrophy, tubulointerstitial fibrosis and tubular apoptosis, and inhibited profibrotic as 
well as pro-apoptotic gene expression. Furthermore, Ang 1-7 through MasR suppressed Agt 
and ACE expression and normalized renal Ace2 and MasR expression in Akita mice. Finally, 
Ang 1-7 suppressed the expression of renal TNF-alpha converting enzyme (TACE) and 
sodium/hydrogen exchanger-3 (NHE-3) in Akita mice.  
 
 
3.3 RESEARCH DESIGN AND METHODS 
 
Chemicals and Constructs 
Ang 1-7 and A-779 (d-Ala-7-Ang I/II/1-7) were purchased from Bachem Americas, Inc. 
(Torrence, CA, USA). A rabbit polyclonal antibody against rat Agt was generated in our lab 
(by J.S.D.C.) [19].  It is specific to intact rat and mouse Agt (55-62 kDa) and does not cross-
react with pituitary hormone preparations or other rat or mouse plasma proteins. Monoclonal 
anti-NHE-3 antibody was a gift from Dr. Orson Moe (UT Southwestern Medical Center, 
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Dallas, TX). The sources of other antibodies were: polyclonal anti-bovine Cat antibody and β-
actin monoclonal antibody (Sigma-Aldrich Canada Ltd.,Oakville, ON, Canada), polyclonal 
anti-heme-oxygenase-1 (HO-1) antibody (Assay Designs, Ann Arbor, MI, USA), monoclonal 
anti-collagen type IV antibody (Chemicon International, Temecula, CA, USA), polyclonal 
anti-transforming growth factor-beta 1 (TGF-β1), anti-NADPH oxidase 4 (Nox4) and anti-
ACE (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-MasR (Novus Canada, 
Oakville, ON, Canada), and anti-TACE (ENZO Life Sciences Inc., Farmingdale, N.Y., USA). 
Polyclonal anti-nuclear factor erythroid 2-related factor 2 (Nrf2) antibody was obtained from 
BD Biosciences (Mississauga, ON, Canada). Oligonucleotides were synthesized by Invitrogen 
(Burlington, ON, Canada). Restriction and modifying enzymes were purchased from 
Invitrogen, Roche Biochemicals, Inc. (Dorval, QC, Canada) and GE Healthcare Life Sciences 
(Baie d'Urfé, QC, Canada). 
 
Ethics Statement  
This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol, 
animal care and experimental procedures were approved by the CRCHUM Animal Care 
Committee. All surgery was performed under sodium pentobarbital anesthesia. Mice were 
euthanized by sodium pentobarbital overdose (75 mg/kg BW), and efforts were made to 
minimize suffering. 
 
Physiological Studies 
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Male heterozygous Akita mice (C57BL/6-Ins2Akita/J) were obtained from Jackson 
Laboratories, Bar Harbor, ME, USA (http://jaxmice.jax.org). Akita mice, an autosomal 
dominant model of spontaneous type 1 diabetes in which insulin gene2 is mutated, have 
decreased numbers of pancreatic islet β-cells and develop hyperglycemia at age 3-4 weeks, 
manifesting impaired renal function with increased oxidative stress markers in their renal 
proximal tubules (RPTs) by age 30 weeks [20, 21] and closely resembling those observed in 
type 1 diabetes patients. Adult Akita mice (age 14 weeks) were treated subcutaneously with 
Ang 1-7 (500 μg/kg-1.day-1) ± A-779 (10 mg/kg-1.day-1) and euthanized at age 20 weeks (8 
mice per group), as described previously [18]. Untreated non-Akita wild type (WT) mice 
served as controls. All animals were given ad libitum access to standard mouse chow and tap 
water.  
Systolic blood pressure (SBP) was monitored in the morning with a BP-2000 tail-cuff 
pressure monitor (Visitech Systems, Apex, NC, USA) at least 2-3 times per week per animal, 
for 10 weeks [14-18, 22-26]. The mice were habituated to the procedure for at least 15-20 min 
per day for 5-7 days before the first SBP measurements. SBP values were expressed as 
means±SEM. All animals were housed individually in metabolic cages for 24 h prior to 
euthanasia at age 20 weeks. Body weight was recorded. Urines were collected and assayed for 
albumin and creatinine by enzyme-linked immunosorbent assays (ELISAs, Albuwell and 
Creatinine Companion (Exocell, Inc., Philadelphia, PA, USA) [14-18, 22-26]. Immediately 
following euthanasia, the kidneys were removed, decapsulated and weighed. The left kidneys 
were processed for histology and immunostaining, and the right kidneys were harvested for 
isolation of RPTs by Percoll gradient [14-18, 22-26]. 
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The glomerular filtration rate (GFR) was estimated as described by Qi et al. [27], as 
recommended by the Animal Models of Diabetic Complications Consortium 
(http://www.diacomp.org/) with slight modifications [18, 22, 28]. 
 
Urinary Ang 1-7 and Ang II Measurement  
Mouse urinary Ang II and Ang 1-7 levels were quantified by specific ELISAs after 
extraction in accordance with the manufacturer`s protocol (Bachem Americas Inc.) and were 
normalized by urinary creatinine levels [17, 18, 22, 25, 26].  
 
Histology  
Four to 5 kidney sections (3-4 μm thick) per kidney from 8 animals per group were 
stained with Periodic acid-Schiff (PAS) or Masson’s trichrome, and assessed by 2 
independent, blinded observers under light microscopy. The collected images were analyzed 
and quantified by the NIH ImageJ software (http://rsb.info.nih.gov/ij/) [14-18, 22-26].  
Mean glomerular volume on 30 random glomerular sections per mouse was assessed by 
Weibel’s method [29] with Motic Images Plus 2.0 analysis software (Motic Instruments, Inc., 
Richmond, BC, Canada) [17, 18, 22, 26]. Tubular luminal areas were measured on renal 
sections (6 animals/group, 4 to 5 sections per kidney, 4 random fields per section, 10 tubules 
around the glomerulus per field) with Motic Images Plus 2.0 analysis software [17, 18, 22, 
26]. Outer cortical RPTs with similar cross-sectional views and clear nuclear structures were 
selected. Mean cell volume was estimated by nucleation [30], as described elsewhere [17, 18, 
22, 26].  
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Immunohistochemical staining was performed according to the standard avidin-biotin-
peroxidase complex method (ABC Staining System, Santa Cruz Biotechnology) [14-18, 22-
26]. Immunostaining with non-immune normal rabbit serum in non-Akita mouse kidneys 
served as control, with no immunostaining being observed (photographs not included). 
Oxidative stress in RPTs in vivo was assessed by staining of frozen kidney sections with 
dihydroethidium (DHE; Sigma-Aldrich Canada Ltd.) and 6-carboxy-2',7'-
dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA; Life Technologies, Burlington, 
ON, Canada) [18, 31]. In these assays, non-fluorescent DHE is oxidized to fluorescent 
ethidium by superoxide anion whereas non-fluorescent carboxy-H2DCFDA is oxidized to 
fluorescent carboxydichlorofluorescein by intracellular ROS (all species). The results were 
confirmed by standard immunohistochemical staining for HO-1, an oxidative stress-inducible 
gene that confers cellular oxidative stress in vivo [18, 25, 32], Nox4 (a constitutively-
expressed and predominant form of Nox in diabetic kidneys) [33, 34] and Nrf2 (a master 
regulator of redox balance in cellular cytoprotective responses) [35]. The percentage of apoptotic 
RPTCs was estimated semiquantitatively by terminal transfer-mediated deoxyuridine 
triphosphate nick end-labeling (TUNEL) assay (Roche Biochemicals, Inc., Laval, QC, 
Canada) [15-18, 22-26].  
 
Real Time-Quantitative Polymerase Chain Reaction (RT-qPCR) Assays for Gene 
Expression 
Agt, ACE, Ace2, MasR, collagen IV, TGF-β1, Nox1, Nox2, Nox4, HO-1, Nrf2, Bax, 
Bcl-xL, TACE, NHE-3 and β-actin mRNA expression in RPTs was quantified by RT-qPCR 
with forward and reverse primers as described [15-18, 22-26] (Supplemental Table I).  
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Western Blotting for Estimation of Protein Expression  
Western blotting for Nox4, Nrf2, HO-1, Agt, Ace2, ACE, MasR, TACE and NHE-3 
performed on RPT lysates [15-18, 22-26]. The membranes were first blotted with anti-Nox4, 
Nrf2, HO-1, Agt, Ace2, ACE, MasR, TACE and NHE-3 antibodies and then re-blotted with 
anti-β-actin monoclonal antibodies and developed with chemiluminescent developing reagent 
(Roche Biochemicals, Inc.). The relative densities of Nox4, Nrf2, HO-1, Agt, Ace2, ACE, 
MasR, TACE, NHE-3 and β-actin bands were quantified by computerized laser densitometry 
(ImageQuant software (version 5.1), Molecular Dynamics, Sunnyvale, CA, USA).  
 
Statistical Analysis 
Statistically significant differences between the experimental groups were analyzed by 
Student’s t-test or one-way ANOVA and Bonferroni correction as appropriate. Data are 
expressed as means ± SEM. P<0.05 was considered to be statistically significant. 
 
 
3.4 RESULTS 
Physiological Parameters in Akita Mice With or Without Ang 1-7 Administration 
We have previously reported significant differences in SBP between Akita and non-
Akita WT mice as early as 8 weeks of age [17, 18, 22, 26]. These differences increased with 
age (from week 14 until week 20). Ang 1-7 administration protected Akita mice against SBP 
elevation compared to non-Akita mice. This protective effect of Ang 1-7 on SBP in Akita 
mice was reversed by A779 co-administration (Table I).  
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At 20 weeks, Akita mice exhibited elevated kidney weight to body weight and heart 
weight to body weight ratios, higher urinary albumin/creatinine ratio (ACR) and GFR than 
non-Akita mice (Table I). Ang 1-7 markedly attenuated these parameters in Akita mice, and 
its effects (except for urinary ACR and GFR) were reversed by A779 co-administration 
(Table I). In contrast, blood glucose levels did not differ significantly in Akita mice with or 
without Ang 1-7 treatment (Table I). 
 
Cat Expression and Oxidative Stress in Akita Mouse Kidneys  
We have reported that Cat expression was RPTC-specific and co-localized to aquaporin-
1-positive RPTCs [18]. We detected lower Cat levels in RPTCs from Akita (Figure 1A, b) 
than in non-Akita WT mice (Figure 1A, a). Ang 1-7 normalized Cat expression in Akita mice 
(Figure 1A, c), and its effect was reversed by A779 (Figure 1A, d). DHE and carboxy-
H2DCFDA staining demonstrated higher levels of oxidative stress in RPTCs from Akita mice 
(Figures 1B and 1C, panels b) than in non-Akita WT mice (Figures 1B and 1C, panels a). Ang 
1-7 decreased oxidative stress in Akita mice (Figures 1B and 1C, panel c), which was reversed 
by A779 (Figures 1B and 1C, panels d). Quantitation of Cat activity, DHE and carboxy-
H2DCFDA staining confirmed these findings (Figures 1D, 1E and 1F, respectively). These 
results confirmed down-regulation of Cat expression and activity in diabetic Akita mice. Ang 
1-7 enhanced Cat expression and activity and effectively attenuated ROS production and its 
effects were reversed by A779 co-administration 
ROS generation (Figure 2A), NADPH oxidase activity (Figure 2B), Nox4 mRNA and 
protein expression (Figure 2C-E) were significantly elevated in the kidneys of Akita than in 
non-Akita mice. Administration of Ang 1-7 normalized these changes and these actions were 
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reversed by A779.  Interestingly, Nox1 and Nox2 mRNA expression did not differ 
significantly among different groups (Figure 2C).  
Consistently, immunostaining for the oxidative stress-inducible proteins Nrf2 and HO-1 
was significantly higher in the kidneys of Akita (Figures 3A and 3B, panels b) than in non-
Akita WT mice (Figures 3A and 3B, panels a). Once again, Ang 1-7 normalized Nrf2 and HO-
1 immunostaining (Figures 3A and 3B, panels c) and these actions were reversed by A779 
(Figures 3A and 3B, panel d). Western blotting for Nrf2 (Figure 3C) and HO-1 (Figure 3D) 
and quantifying Nrf2 mRNA (Figure 3E) and HO-1 mRNA expression (Figure 3F) confirmed 
these findings. Collectively, these results document Ang 1-7 attenuation of enhanced oxidative 
stress in diabetic Akita mice.    
 
Effect of Ang 1-7 on Agt, Ace2, ACE, MasR, TACE and NHE-3 Expression in Akita 
Kidneys  
Consistent with previous observations [17, 18, 22, 26], Agt immunostaining was 
increased significantly in Akita mice (Figure 4A, b) compared to WT controls (Figure 4A, a). 
Ang I-7 attenuated Agt expression in Akita mice (Figure 4A, c), and its effect was reversed by 
A779 (Figure 4A, d). Quantitation of Agt protein and Agt mRNA expression by respective 
WB and qPCR confirmed these findings (Figure 4B and 4C, respectively). Furthermore, 
urinary Ang II levels were significantly higher in Akita than in non-Akita WT mice (Figure 
4D). Ang 1-7 normalized urinary Ang II levels in Akita mice with reversal by A779. In 
contrast, urinary Ang 1-7 levels were significantly lower in Akita mice than in non-Akita WT 
mice (Figure 4E). Ang 1-7 administration normalized urinary Ang 1-7 levels in Akita mice 
with partial, statistically not significant reversal by A779. 
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The RPTCs of WT controls (Figure 5A, a) exhibited decreased ACE staining relative to 
Akita mice (Figure 5A, b).  Ang 1-7 normalized ACE immunostaining with reversal by A779 
co-administration in RPTCs from Akita mice (Figure 5A, c and d, respectively). In contrast, 
Ace2 and MasR expression in the RPTCs of non-Akita WT controls (Figures 5B and 5C, 
panels a respectively) was significantly higher than in Akita mice (Figure 5B and 5C, panels b, 
respectively). Ang 1-7 normalized Ace2 and MasR immunostaining in RPTCs of Akita mice  
Figures 5B and 5C, c respectively), and  its effects were  reversed by A779 co-administration ( 
Figures 5B and 5C, panels d, respectively). We confirmed these findings by immunoblotting 
and qPCR for ACE, Ace2 and MasR protein (Figure 5D) and their respective mRNA 
expression in isolated RPTs (Figure 5E) 
In contrast to Ace2 and MasR expression,  TACE and NHE-3 expression (Figures 6A 
and 6B, b) were reduced in RPTCs of Akita mice as compared to WT mice (Figures 6A and 
6B, a). Ang 1-7 administration normalized TACE and NHE-3 expression in Akita mice 
(Figures 6A and 6B, c). These actions were reversed by A779 (Figures 6A and 6B, d). These 
findings were confirmed by immunoblotting for TACE and NHE-3 protein (Figures 6C and 
6D, respectively) in freshly isolated RPTs. TACE and NHE-3 mRNA levels, however, did not 
differ among different groups (Figures 6E and 6F, respectively), as quantified by qPCR.  
 
 Effect of Ang 1-7 on Renal Fibrosis and Profibrotic Gene Expression in Kidneys of Akita 
Mice 
Unlike WT non-Akita mice (Figure 7A, a), Akita mice exhibited renal structural damage 
(Figure 7A, b). Histological findings included tubular luminal dilatation and accumulation of 
cell debris in the tubular lumen. Some RPTCs were flattened. Remarkably, Ang 1-7 
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administration in Akita mice markedly suppressed, but never completely prevented these 
abnormalities (Figure 7A, c). A779 co-administration partially reversed Ang 1-7’s effect 
(Figure 7A, d). We observed significantly-increased glomerular tuft volume, tubular luminal 
area and RPTC volume in Akita compared to non-Akita WT mice (Table I). Ang 1-7 partially 
reduced tubular luminal area and glomerular tuft volume, and completely normalized RPTC 
volume in Akita mice. Again, co-A779 administration partially reversed the effect of Ang 1-7 
on these parameters (Table I).  
We assessed the expression of collagenous components with Masson's trichrome 
staining (Figure 7B) and immunostaining for collagen type IV (Figure 7C) and TGF-β1 
(Figure 7D). Kidneys from non-Akita WT exhibited significantly lower collagenous contents, 
collagen type IV and TGF-β1 (Figures 7B, 7C and 7D, panels a, respectively) relative to Akita 
mice (Figures 7B, 7C and 7D, panels b, respectively). Ang 1-7 markedly reduced 
glomerulotubular fibrosis (Figures 7B, 7C and 7D, panels c, respectively), and its effect was 
reversed by A779 co-administration Figures 7B, 7C and 7D, panels d, respectively). 
Quantitative analysis of Masson’s trichrome staining (Figure 7E) and collagen 
immunostaining (Figure 7F), collagen IV mRNA (Figure 7G) and TGF-β1 mRNA (Figure 7H) 
expression confirmed these findings. Collectively, the data indicated that Ang 1-7 effectively 
prevented renal fibrosis in Akita mice. 
 
Effect of Ang 1-7 on Tubular Apoptosis in Akita Kidneys 
Next, we investigated the impact of Ang 1-7 administration on tubular apoptosis in 
Akita mice by TUNEL assay. The number of TUNEL-positive nuclei in RPTCs from non-
Akita WT mice (Figure 8A, a) were significantly lower than in Akita mice (Figure 8A, b). 
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Ang 1-7 significantly reduced the number of TUNEL-positive cells in Akita mice (Figure 8A, 
c) and its effect was reversed by A779 (Figure 8A, d). Consistently, active (cleaved) caspase-3 
expression was lower in RPTCs from non-Akita WT controls (Figure 8B, a) but higher in 
Akita mice (Figure 8B, b). Ang 1-7 attenuated active caspase-3 expression in Akita mice 
(Figure 8B, c) with its reversal by A779 (Figure 8B, d). Quantitation of TUNEL-positive cell 
numbers (Figure 8C) and caspase-3 activity assays in isolated RPTs (Figure 8D) confirmed 
these findings. 
Akita mice exhibited increased Bax mRNA expression (Figure 8E) and decreased Bcl-
xL mRNA expression (Figure 8F) compared to non-Akita WT mice. These changes were 
normalized in Akita mice by Ang 1-7 and the actions of Ang 1-7 were reversed by A779 
(Figures 8E and 8F).  
 
3.5 DISCUSSION 
Our study demonstrates that Ang 1-7 treatment in Akita mice effectively attenuates 
oxidative stress, normalizes Ace2 and MasR expression in RPTCs, and suppresses expression 
of pro-hypertensive, pro-fibrotic and pro-apoptotic proteins. These findings indicate an 
important role for Ang 1-7 in regulating renal oxidative stress and subsequently modulating 
sHTN and kidney injury in vivo. 
Expanding our previous findings that Cat overexpression in RPTCs normalizes Ace2 
expression and prevents hypertension, reduces tubulointerstitial fibrosis and RPTC apoptosis 
in Akita Cat-Tg mice [18], here, we show that Ang 1-7 attenuates  sHTN, indicating that 
intrarenal Ang 1-7 formation is critical for counteracting Ang II’s impact in Akita mice. These 
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observations highlight an important role of intrarenal Ace2 expression and Ang 1-7 formation 
in thwarting hypertension and nephropathy development in diabetic mice.  
The mechanisms underlying SBP elevation in Akita mice are largely unknown. The 
possibility that down-regulation of Ace2 and Mas receptor gene expression and consequently 
high Ang II/Ang 1-7 ratios facilitate the development of hypertension has received 
considerable attention [5-7]. Indeed, our present findings demonstrate significantly lower 
RPTC Ace2, MasR and urinary Ang 1-7 and higher RPTC ACE and urinary Ang II levels in 
Akita mice than in non-Akita WT. Ang 1-7 normalized these changes and A779 co-
administration reversed the effects of Ang 1-7. These observations are consistent with our 
previous findings of markedly-elevated ACE and depressed Ace2 expression in the kidneys of 
Akita Agt-Tg mice [17] as well as with studies on normotensive Lewis rats, which showed 
that RAS blockade increases cortical Ace2 activity and urinary Ang 1-7 excretion [36]. 
Normal human kidneys express low ACE and high Ace2 levels, and this ratio is reversed in 
the kidneys of hypertensive and diabetic patients [37-39]. Furthermore, Ang II has been 
observed to up-regulate ACE and down-regulate Ace2 expression in HK2 cells in vitro [37]. 
Taken together, our current data lend support to the concept that intrarenal RAS activation up-
regulates Agt and ACE expression and down-regulates Ace2 and Mas receptor expression via 
enhanced oxidative stress in RPTCs, ultimately contributing to hypertension development.  
The mechanisms underlying the antihypertensive action of Ang 1-7 are not well-defined. 
One possibilty is that Ang 1-7 prevents or attenuates the influence of Ang II on glomerular 
arterioles, thereby lowering glomerular pressure (hyperfiltration), glomerular tuft volume and, 
eventually, SBP.  This possibility is supported by the studies by Benter et al [9, 10], which 
showed that Ang 1-7 reduces renal vascular resistance in diabetic hypertensive rats. 
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Furthermore, other studies have shown that recombinant human Ace2 attenuates Ang II-
dependent and pressure-overload-induced hypertension in Ace2 knockout mice [40-42], 
supporting an important counterregulatory role for Ang 1-7 in Ang II-mediated sHTN and 
renal abnormalities. 
Another possibility is that Ang 1-7 could affect TACE (an enzyme responsible for Ace2 
shedding) and NHE-3 (a key transporter mediating sodium reabsorption in the RPTs). Indeed, 
our data show increased renal TACE and NHE-3 expression in the RPTCs of Akita mice as 
compared to WT mice. Ang 1-7 administration normalized these changes and the effects of 
Ang 1-7 were reversed by A779.  These findings suggest that the SBP lowering action of Ang 
1-7 is mediated, at least in part, via down-regulation of TACE and NHE-3 expression in the 
RPTs in Akita mice.  
Since glomerular hyperfiltration and microalbuminuria are early clinical markers of 
hypertension- or diabetes-induced nephropathy, we monitored the GFR and urinary 
albuminuria, and detected enhanced GFR and microalbuminuria in Akita mice at age 20 
weeks. Ang 1-7 significantly reduced, but never completely prevented these changes. 
Surprisingly, A779 co-administration could not completely overturn Ang 1-7’s effect on the 
GFR and albuminuria despite complete reversal of SBP in Akita mice. The exact reasons for 
such discordant inhibitory actions remain largely unknown. One possibility is that different 
subtype(s) of Ang 1-7 receptor might be present in podocytes that are less sensitive to A779 
inhibition. This notion is further supported by the studies of Silva et al [43], which showed 
that Ang 1-7 receptor is sensitive to D-pro7-Ang 1-7 but not to A779 in the aorta of Sprague-
Dawley rats. Clearly, additional studies are needed to address this issue in podocytes. 
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The mechanism by which oxidative stress leads to interstitial fibrosis in Akita mice is far 
from being fully understood. It is possible that augmented ROS generation via enhanced 
Agt/Ang II expression would stimulate TGF-β1, subsequently heightening the expression of 
extracellular matrix proteins, collagen type IV, profibrotic and pro-apoptotic proteins in 
RPTCs, with resultant apoptosis and, ultimately, interstitial fibrosis [44]. Indeed, neutralizing 
TGF-β alleviates fibrosis and tubular cell apoptosis in animal models of diabetes [45]. Our 
present study shows higher TGF-β1 and collagen IV expression in RPTs from Akita than non-
Akita mice. Ang 1-7 mitigated these changes, thus linking intrarenal oxidative stress to 
interstitial fibrosis. 
To further investigate the role of oxidative stress in mediating the underlying 
mechanism(s) of Ang 1-7 action on SBP regulation, we treated Akita mice with the ROS 
scavenger tempol (4-hydroxy-tempol) or with tempol and Ang 1-7. Confirming the 
observations of Fujita et al [46], tempol had no effect on SBP, whereas it attenuated renal 
oxidative stress in Akita mice (Supplemental Figure 1). In contrast, co-administration of 
tempol and Ang 1-7 effectively lowered SBP and reduced renal oxidative stress in Akita mice. 
The reasons why tempol failed to lower SBP in Akita mice are not known at the present.  
Confirming our previous findings in Akita kidneys [17, 18, 22, 26], we detected higher 
number of  apoptotic RPTCs in Akita mice, evidenced by higher percentages of TUNEL-
positive RPTCs in parallel with increased active caspase-3 immunostaining and Bax mRNA 
expression and decreased Bcl-xL mRNA expression. Elevated Bax/Bcl-xL ratios are 
consistent with tubular apoptosis in Akita mice. Once again, these changes were mitigated in 
Akita mice by Ang 1-7 and the actions of Ang 1-7 were reversed by A779. 
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Our results may have clinical implications for the assessment of progression in type 1 
diabetes. Tubulointerstitial fibrosis and tubular apoptosis occur in the kidney in human type 1 
diabetes  [47], and tubular atrophy appears to be a better indicator of disease progression than 
glomerular pathology  [48]. We postulate that tubulointerstitial fibrosis and RPTC apoptosis 
may be the initial events leading to tubular atrophy in diabetes. Oxidative stress-mediated 
decreases of Cat, Ace2 and MasR expression could further accelerate this process.  
In summary, our data indicate an important role of Ang 1-7 in inhibiting intrarenal 
oxidative stress and subsequent prevention of the development of hypertension and renal 
injury in Akita mice.  
 
 
 
 
3.6 CLINICAL PERSPECTIVES 
1. Enhanced intrarenal Agt gene expression/RAS activation induces systemic 
hypertension and kidney injury in diabetes and its effects can be countered by Ang 1-7; 
However, the molecular mechanism(s) underlying the beneficial actions of Ang 1-7 on 
systemic hypertension and kidney injury are not fully understood.  
2. In the present study in diabetic Akita mice, Ang 1-7 administration normalized 
systemic hypertension and attenuated glomerular injury and tubulointerstitial fibrosis. 
Ang 1-7 decreased oxidative stress and expression of pro-hypertensive genes, and 
normalized the expression of Ace2 and MasR in the kidneys.  Co-administration of 
A779, an antagonist of MasR effectively reversed most of the effects of Ang 1-7. 
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3. Our results indicate the potential of Ang 1-7 as a therapeutic agent for treatment of 
systemic hypertension and kidney injury in diabetes.  
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3.9 Legends and Figures 
Table 3-1. Physiological Measurements 
 
WT Akita 
Akita + 
Ang 1-7 
Akita + 
Ang 1-7 + A779 
(A) Systolic blood 
pressure (SBP) 
107.00±0.79 136.50±2.83 117.6±1.09 133.9±2.47 
(B) Blood Glucose 
(mmol/L) 
9.51±0.75 
 
35.47±0.72*** 
 
35.19±0.52*** 
 
35.28±0.65*** 
 
(C) Body Weight 
(BW) (g) 
30.62±0.70 
 
24.4±0.45*** 23.5±0.40*** 24.43±0.44*** 
(D) Kidney Weight 
(KW) (mg) 
366.2±8.14 
 
547.6±18.42*** 415.6±13.03††† 429±12.15††† 
(E) KW/BW ratio 
(mg/g) 
11.85±0.29 20.28±0.37*** 18.2±0.64***,†† 17.26±0.24***,††† 
(F) GFR (uL/min)/ 
BW (g) 
10.20±0.79 22.00±1.96 *** 16.03±0.92 **,† 19.68±1.17 *** 
(G) ACR  
(μg/ml/mg/dL) 
0.28 ±0.02 
 
3.14 ±0.87*** 
 
0.67 ±0.16††† 
 
0.70 ±0.13††† 
 
(H) Glomerular tuft 
volume (X 103 μm3) 
110.3 ±12.17 
 
178.2 ±15.36** 
 
125.2 ±11† 
 
148.7 ±8.31 
 
(I) RPTC volume 
(X 103 μm3) 
6.12 ±0.26 
 
10.77 ±0.39*** 
 
6.76 ±0.22††† 
 
10.92 ±0.30*** 
 
(J) Tubular 
laminar Area 
(μm2) 
86.51±2.28 
 
184.00±5.32 
 
96.42±6.23††† 
 
177.00±3.42*** 
 
 
*P<0.05 **P<0.01 and ***P<0.005 vs WT; †P<0.05 ††P<0.01 and †††P<0.005 vs Akita mice 
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Figure 3-1: Immunohistochemical staining for Cat (A), dihydroethidium (DHE) (red) (B) and 
6-carboxy-2',7'-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) (green) (C) in 
male mouse kidneys at age 20 weeks. Magnification X200. Quantitation of Cat activity (D) 
and semi-quantitation of DHE (E) and carboxy-H2DCFDA (F) fluorescence in mouse kidneys. 
Values are expressed as means ± SE (n=8 per group). *P<0.05, ***P<0.005, N.S., non-
significant. 
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Figure 3-2: ROS generation, NADPH oxidase activity, Nox 1, 2 and 4 expression in mouse 
RPTs at age 20 weeks. ROS generation (A) and NADPH oxidase activity (B) were quantified 
by lucigenin assays.  Nox1, Nox2 and Nox 4 mRNA expression in mouse RPTs were 
quantified by qPCR (C). Immunostaining (D) and Western blotting (E) for Nox4 in mouse 
RPTs. Membranes were blotted for Nox4, then re-blotted for β-actin. Nox4 levels were 
normalized by corresponding β-actin levels. Corresponding values in non-Akita control 
littermates were considered as 100%. Values are expressed as means±SEM (n=8). *P<0.05, 
**P<0.01, ***P<0.005, N.S., non-significant. 
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Figure 3-3: Nrf2 and HO-1 expression in mouse kidneys at age 20 weeks. Nrf2 (A) and HO-1 
(B) immunostaining. Magnification X200. Semi-quantitation of WB of Nrf2 (C) and HO-1 (D) 
in mouse kidneys. Values in non-Akita control littermates were considered as 100%. 
Quantitation of Nrf2 (E) and HO-1 (F) mRNA level by qPCR in mouse kidneys. Values in 
non-Akita control littermates were considered as arbitrary unit 1. Values are expressed as 
means ± SE (n=6). *P<0.05, **P<0.01, ***P<0.005, N.S., non-significant. 
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Figure 3-4: Agt expression in mouse kidneys at age 20 weeks. Agt (A) immunostaining. 
Magnification X200. Western blotting of Agt protein (B) and qPCR of its mRNA level (D) in 
mouse RPTs. Values in non-Akita control littermates were considered as 100% control or 
arbitrary unit 1 . Values are expressed as means ± SE (n=8). **P<0.01, ***P<0.005, N.S., 
non-significant. Urinary Ang II (D) and Ang 1-7 (E) levels. Urinary Ang II and Ang 1-7 levels 
in non-Akita control littermates were expressed as controls. Values are expressed as means ± 
SE (n=8). *P<0.05, **P<0.01, ***P<0.005, N.S., non-significant. 
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Figure 3-5: Immunostaining for ACE (A), Ace2 (B) and MasR (C) expression in mouse 
kidneys at age 20 weeks. Magnification X200. Western blotting of ACE, Ace2 and MasR (D) 
in mouse RPTs. Membranes were re-blotted for β-actin. ACE, Ace2 and MasR levels were 
normalized by corresponding β-actin levels. Values in non-Akita control littermates were 
considered as 100% control. q-PCR of ACE, Ace2 and MasR mRNA levels in mouse kidneys 
(E). Values in non-Akita control littermates were considered as arbitrary unit 1. Values are 
expressed as means ± SE (n=8). *P<0.05, ***P<0.005, N.S., non-significant. 
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Figure 3-6: Immunostaining for TACE (A) and NHE-3 (B) in mouse kidneys at age 20 weeks. 
Magnification X200. Western blotting of TACE (C) and NHE-3 (D) in mouse RPTs. 
Membranes were re-blotted for β-actin. TACE and NHE-3 levels were normalized by 
corresponding β-actin levels. Values in non-Akita control littermates were considered as 100% 
(control). q-PCR of TACE (E) and NHE-3 (F) mRNA levels in mouse RPTs. Values in non-
Akita control littermates were considered as arbitrary unit 100%. Values are expressed as 
means ± SE (n=8). *P<0.05, **P<0.01, N.S., non-significant. 
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Figure 3-7: PAS staining (A) and Masson’s trichrome staining (B) (magnification X600) and 
immunostaining for collagen IV (C) and TGF-β1 (D) (magnification X200) expression in 
mouse kidneys at age 20 weeks. (E) Quantification of extracellular matrix component 
accumulation (Masson’s trichrome staining). (F) Quantitation of immunoreactive collagen IV 
deposition. (G) qPCR of collagen IV (G) and TGF-β1 (H) mRNA level in mouse kidneys. 
Values in non-Akita control littermates were considered as 100% control. Values are 
expressed as means ± SE (n=8). **P<0.01, ***P<0.005, N.S., non-significant. 
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Figure 3-8: Apoptosis in mouse kidneys at age 20 weeks. (A) TUNEL staining (green) and (B) 
Immunostaining for cleaved (active) caspase-3. Magnification X200. Semi-quantitation of 
apoptotic RPTCs (C) and (D) caspase-3 activity in isolated RPTs. RT-qPCR for Bax (E) and 
Bcl-xL (F) mRNA. Assays were run simultaneously for Bax, Bcl-xL and β-actin mRNAs. Bax 
and Bcl-xL mRNA levels were normalized by corresponding β-actin mRNA levels. mRNA 
levels in non-Akita control littermates were considered as 100%. Values are expressed as 
means ± SE (n=8). *P<0.05, **P<0.01, ***P<0.005, N.S., non-significant.  
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Supplemental Table 1 (Primers) 
 
Gene Primer sequences Species Reference 
 Sequence
NOX1 S: GGTCACTCCCTTTGCTTCCA 
AS: GGCAAAGGCACCTGTCTCTCT 
 
Mouse 
 
NM_172203.2 
NOX2 S: CCCTTTGGTACAGCCAGTGAAGAT 
AS : CAATCCCGGCTCCCACTAACATCA 
 
Mouse 
 
NM_007807.5 
NOX4 S: TGGCCAACGAAGGGGTTAAA   
 AS : GATGAGGCTGCAGTTGAGGT Mouse NM_001285835.1
HO-1 S: CACCAAGTTCAAACAGCTCT   
 AS: CAGGAAACTGAGTGTGAGGA Mouse NM_010442.2 
Nrf2 S: CGCCGCCTCACCTCTGCTGCCAGTAG 
AS: AGCTCATAATCCTTCTGTCG 
 
Mouse 
 
NM_010902.3 
Agt S: ACAGACACCGAGATGCTGTT 
AS: CCACGCTCTCTGGATTTATC 
 
Mouse 
 
NM_007428.3 
ACE S: GACCGGACAGCCCAAGTG   
 AS: AGCTTCTTTATGATCCGCTTGATG Mouse NM_207624.5 
Ace2 S: ATATGACTCAAGGATTCTGGG   
 AS: GCTGCAGAAAGTGACATGATT Mouse NM_001130513.1
MasR S: GCATTCGTCTGTGCCCTTCT   
 AS: TTCCGTATCTTCACCACCAAGA Mouse NM_008552.4 
TACE S: AGAGAGCCATCTGAAGAGTTTGT   
 AS: TTATCCCACGACGTGTTCCG Mouse NM_001277266.1
NHE3 S: AGGTGGTCACCTTCAAATGGC 
AS: GGGACAGGTGAAAGACGATTT 
 
Mouse 
 
NM_001081060.1
Col IV S: CATGTCCATGGCACCCATCT   
 AS: ATGGCCGGTGCTTCACAAAC Mouse NM_009931.2 
TGF-β1 S: CCAAACTAAGGCTCGCCAGTC   
 AS: GGCACTGCTTCCCGAATGTC Mouse NM_011577.1 
Bax S: TCATGAAGACAGGGGCCTTTT   
 AS: CAATCATCCTCTGCAGCTCCA Mouse NM_007527.3 
Bcl-xL S: TACCGGAGAGCGTTCAGTGATCTA   
 AS: CTGCATCTCCTTGTCTACGCTTTC Mouse NM_009743 
β-Actin S: CGTGCGTGACATCAAAGAGAA   
 AS: GCTCGTTGCCAATAGTGATGA Mouse NM_007393 
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In our studies, Tg mice overexpressing Cat were created to investigate whether the oxidative 
stress is involved in the development of hypertension and nephropathy in Akita mice via 
down-regulation of renal ACE2 expression. We found that overexpression of Cat attenuated 
renal oxidative stress; prevented hypertension; ameliorated glomerular filtration rate, 
albuminuria, kidney hypertrophy, tubulointerstitial fibrosis, and tubular apoptosis; and 
suppressed profibrotic and proapoptotic gene expression in RPTCs of Akita Cat-Tg mice 
compared with Akita mice. Furthermore, overexpression of Cat in RPTCs of Akita mice 
normalized renal ACE2 expression and urinary Ang 1–7 levels. These findings confirmed our 
hypothesis.  
Next, we investigated the impact of Ang 1-7 on hypertension, oxidative stress and kidney 
injury in diabetic Akita mice by injecting Akita mice with Ang 1-7. The administration of Ang 
1-7 also attenuated oxidative stress and the expression of NADPH oxidase 4, Agt, ACE, TGF-
β1 and collagen IV, and increased the expression of ACE2 and MasR in Akita mouse kidneys. 
These effects were reversed by co-administration of A779. Our data suggest that Ang 1-7 
plays a protective role in hypertension and RPTC injury in diabetes, predominantly through 
decreasing renal oxidative stress-mediated signaling and normalizing ACE2 and Mas receptor 
expression. 
 
4.1 Intrarenal RAS and ACE2 in DM 
In the kidney, all major components of the RAS, including the precursor Agt, the rate-limiting 
enzyme renin and ACE, and the receptors for Ang II (AT1R and AT2R), ACE2, Ang 1-7  and 
its receptor (MasR) have been demonstrated [251]. Indeed, human and murine RPTCs express 
all components of the RAS [136, 252]  
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The main effector of classic RAS system, Ang II, has the effect of vasopressor, inflammation, 
hypertrophy, pro-fibrotic and pro-apoptotic. On the opposite, Ang 1-7 exhibits anti-
hypertensive, anti-inflammatory, anti-hypertrophic, anti-fibrotic and anti-apoptotic properties. 
Therefore, ACE2/ Ang 1-7/ MAS axis can counteract ACE/ Ang II /AT1R axis. 
It is well accepted that in the hyperglycemic milieu, RAS system is activated. An increase in 
intrarenal Agt mRNA has been reported in diabetic rats, implying increased Agt synthesis by 
the proximal tubule [182, 253]. In vitro studies has shown that high extracellular glucose 
stimulates the synthesis of Agt in a concentration-dependent manner, via PKC [254], or via 
ROS in the rat proximal tubule [255]. These findings are confirmed by our observation in 
Akita TID mice (Fig. 3Aa, 3d, 3g. page 92). 
On the other hand, ACE2 expression is suppressed in DM. Tubular ACE2 mRNA and protein 
expression were reduced in male Sprague-Dawley rats with STZ -induced diabetes after 24 
weeks [193], and in male C57Bl/6 STZ-diabetic mice, which was associated with a reduction 
in kidney cortical levels of Ang 1–7 [256]. Within the glomerulus,  ACE2 protein expression 
in podocyte from T2D db/db mice was decreased, whereas ACE protein expression, by 
contrast, was increased [187]. Similarly, glomerular ACE2 mRNA and protein was reduced in 
STZ-induced C57BL/6J mice [257]. Consistent with the results from experimental diabetes, 
renal biopsy studies from humans with type II diabetic nephropathy showed that decreased 
ACE2 and increased ACE expression in both the tubulointerstitium and glomeruli resulted in a 
significant increase in ACE/ACE2 ratio in patients with diabetes with overt nephropathy 
compared with controls [191]. Similarly, Reich et al. [192] found a significant decrease in 
ACE2 mRNA expression in laser captured glomeruli and proximal tubules from patients with 
T2D and diabetic nephropathy, accompanied by enhanced expression of ACE mRNA in both 
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compartments. ACE2 protein expression was significantly reduced in proximal tubules from 
diabetic subjects as well by immunohistochemistry. Our studies confirmed that ACE2 
expression was downregulated at both mRNA and protein levels in Akita mice (Fig. 3B, 3E 
and 3H, page 92), compared with WT mice. 
 
4.2 Tg mouse model overexpressing Cat in the RPTCs 
To create Tg mice overexpressing Cat in the RTPCs, we inserted rat Cat cDNA fused with an 
HA tag (a sequence encoding amino acid residues 98 to 106 (YPYDVPDYA) of human 
influenza virus hemagglutinin) at the 3’ terminal into a construct containing the kidney 
androgen regulated promoter, pKAP2. The KAP promoter can drive the targeted gene to 
express in the RPTCs in response to testosterone stimulation. We chose male Tg mice, which 
had enough endogenous testosterone to induce Tg gene expression. Then we crossbred male 
heterozygous Akita mice with female homozygous Cat Tg mice to obtain the Akita Cat-Tg 
mice. 
We confirmed the presence of Cat in RPTCs by immune-staining. In the kidney, Cat is 
localized predominantly in the cytoplasm of proximal tubules of the superficial cortex. Cat 
was not detected in the glomeruli, distal tubules, loop of Henle, and collecting ducts [52]. To 
clearly show the location of RPTC, a biomarker, aquaporin 1, was chosen. Aquaporins (AQPs) 
are a class of membrane water channels whose primary function is to facilitate the passive 
transport of water across the plasma membrane of the cell in response to osmotic gradients 
that are created by the active transport of solutes [258]. There are at least 11 AQPs, of which, 
AQP1 is expressed in the RPT and the thin descending limb of the loop of Henle, but not in 
the distal tubule or collecting duct [258]. The co-localization of Cat and AQP1 confirmed the 
 
 
147 
presence of Cat in RPTC (Fig. 1C, page 88). Furthermore, Cat levels were significantly higher 
in RPTCs in Cat-Tg mice (Fig. 1Bb) and Akita Cat-Tg mice (Fig. 1Bd) than in non-Akita WT 
mice (Fig. 1Ba) or in Akita mice (Fig. 1Bc). These results confirmed that the KAP gene 
promoter directs Cat Tg expression in the RPTCs of Cat-Tg and Akita Cat-Tg mice. 
To assess the oxidative stress, different methods were employed. Heme oxygenase-1 (HO-1) is 
an enzyme that catalyzes the degradation of heme and is inducible in response to oxidative 
stress [259]. Thus, increased cellular expression of HO-1 has been considered to be a marker 
of oxidative stress [260]. Dihydroethidium (DHE) has been extensively used to evaluate ROS 
production in vivo. It is freely permeable and after entry it is oxidized to fluorescent ethidium 
bromide (EB) in the presence of O2-. Ethidium bromide is a potent mutagen and it is trapped 
intracellularly by intercalation into the DNA. In our experiment, both HO-1 immunostaining 
and DHE staining showed significantly higher oxidative stress in Akita mice (Fig. 1, Dc and 
Ec, page 88) than in non-Akita WT mice (Fig. 1, Da and Ea, page 88). This is consistent with 
the finding that high glucose can induce the ROS generation [124]. Cat is an antioxidant 
enzyme and can convert H2O2 to water and oxygen, thus mitigating the toxic effect of H2O2. 
Cat overexpression in Akita Cat-Tg could effectively attenuate oxidative stress, as shown in 
Fig. 1, Dd and Ed, page 88. 
 
 4.3 ACE2, Ang 1-7 and hypertension in diabetic mice 
Activation of intrarenal RAS can lead to systemic hypertension in diabetic condition. Within 
the kidney, AT1 receptors are expressed on epithelial cells throughout the nephron, in the 
glomerulus, and on the renal vasculature [261, 262]. First, renal Ang II might exert a vaso-
constrictive effect on glomerular arterioles via AT1R. Second, Ang II may elicit hypertension 
 
 
148 
through changes in sodium or fluid homeostasis, possibly via alterations in transport 
mechanisms in the kidneys. In the proximal tubule, Ang II promotes sodium reabsorption by 
co-ordinately stimulating the sodium-hydrogen exchanger on the luminal membrane along 
with the Na+/K+-ATPase on the basolateral surface [263, 264]. In the collecting duct, Ang II 
directly stimulates ENaC activity via AT1 receptors [265].  Renal vasoconstriction caused by 
Ang II reduces medullary blood flow and blunts the kidney’s excretory capacity for sodium 
[266, 267]. 
 
ACE2 have beneficial effects on the regulation of blood pressure, because it degrades 
vasoconstrictor Ang II as well as produces vasodilator Ang 1-7. ACE2-deficient C57BL/6 
mice have raised basal blood pressure, with notable amplifications of Ang II-induced 
hypertension, which was  associated with exaggerated accumulation of Ang II in the kidney 
after Ang II infusion [198]. On the opposite, overexpression of ACE2 in the rostral 
ventrolateral medulla [268], the paraventricular nucleus [269] or the whole brain [270] have 
attenuated high blood pressure and improved baroreflex dysfunction induced by Ang II [270]. 
Tg rats with ACE2 overexpression in blood vessels of SHRSP rats reduced blood pressure and 
improved endothelial function [271]. Pharmacological intervention studies have revealed 
similar beneficial effects of ACE2 on high blood pressure. Systemic administration of human 
recombinant ACE2 counteracted pressor effects induced by Ang II and resulted in a decrease  
in blood pressure [247, 272]. 
The effect of ACE2 on regulation of blood pressure might be the result of less Ang II, more 
Ang 1-7 or both.  In contrast with the reported beneficial effects of ACE2 on hypertension, 
studies with Ang 1–7 have yielded rather contradictory results. For instance, Giani et al. [273] 
reported Ang 1-7 attenuation of systolic blood pressure in Zucker rats. A transient decrease in 
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BP has also been observed with intravenous infusion of Ang 1–7 in SHR [207]. Iyer et al 
[274] revealed an important contribution of Ang 1–7 in mediating the antihypertensive effects 
caused by combined inhibition of ACE and AT1 receptors in SHR. This is because plasma 
levels of Ang 1-7 were elevated after combined inhibition and treatment with an antibody 
against Ang 1–7 induced a significant elevation in systolic BP. In contrast, Tan et al. [275] 
found no significant reductions in SBP in response to Ang 1-7 in SHR and Wistar-Kyoto rats. 
In our studies, we found that Ang 1-7 administration indeed prevented systemic hypertension 
and A-779 could reverse the BP (Fig. 6, page 98). However the mechanisms underlying the 
antihypertensive action of Ang 1-7 are not well-defined. One possibility is that Ang 1-7 exerts 
a vaso-dilatory effect that involves release of endothelial derived nitric oxide, production of 
vasodilator prostaglandins, and potentiation of the hypotensive effects of bradykinin [201]. 
Furthermore, Ang 1-7 possesses natriuretic/diuretic properties in vivo. In anesthetized rats, 
administration of Ang 1-7 increases urinary flow rate and sodium excretion, an effect 
abolished by A-779 [211]. In vitro studies also showed that Ang 1-7 could limit trans-cellular 
sodium transport. For instance, in cultured rabbit proximal tubular cells, Ang 1-7 inhibits 
sodium flux through the activation of phospholipase A2 [210]. In isolated rat proximal tubules, 
Ang 1-7 inhibits the ouabain-sensitive Na+/K+-ATPase [211]. Our studies showed that the 
RPTCs of Akita mice exhibited increased renal NHE-3 expression as compared to WT mice. 
Ang 1-7 administration normalized NHE-3 expression in Akita mice and reversed by A779 
co-administration. These findings suggest that Ang 1-7 lowering SBP in Akita mice might be 
mediated, at least in part, via down-regulation of NHE-3 expression in the RPTs in Akita 
mice. 
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4.4 Antioxidants and hypertension 
The antioxidants vitamins C and E and other antioxidants have been considered as possible 
therapy for decreasing oxidative stress and thereby lowering blood pressure. 
In experimental models of hypertension, vitamin C, alone or in combination with vitamin E, 
reduces blood pressure [276, 277]. In spontaneously hypertensive rats (SHR), dietary 
supplementation of α-tocopherol for 3 months prevented development of increased blood 
pressure and reduced lipid peroxides in plasma and vessels [278]. However, long-term clinical 
trials have failed to consistently support the antihypertensive effects of antioxidants. For 
instance, one of the largest trials, performed by the Heart Protection Collaborative Group, 
found no improvement in BP after treatment with a combination of ascorbic acid, synthetic 
vitamin E, and β-carotene versus placebo after 5 years in 20 536 UK adults (aged 40–80) with 
coronary disease, other occlusive arterial disease, or diabetes [279]. Possible reasons for these 
disappointing outcomes relate to 1) type of antioxidants used, 2) patient cohorts included in 
trials, and 3) the trial design itself. With regard to antioxidants, it is possible that agents 
examined were ineffective and non-specific and that dosing regimens and duration of therapy 
were insufficient [280]. Another possibility is that orally administered antioxidants may be 
inaccessible to the source of free radicals, especially if ROS are generated in intracellular 
compartments and organelles. Moreover, antioxidant vitamins do not scavenge H2O2, which 
may be more important than •O2- in cardiovascular disease [280]. In our Akita Cat-Tg mice, 
Cat expressed in RPTCs can eliminate intracellular H2O2 and therefore more effectively 
ameliorates oxidative stress. If we specifically deliver Cat gene to the kidney or using specific 
molecule to activate the expression of Cat, we might obtain a good therapeutic way to reduce 
BP and ameliorate kidney injury in human condition.  
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Another factor of importance is that antioxidants do not inhibit ROS production [280]. In our 
experiment, infusion of Ang 1-7 could inhibit the ROS generation, especially that from 
NADPH oxidase. Therefore Ang 1-7 might be a potential therapeutic agent for treatment of 
systemic hypertension.  
 
4.5 ROS, Cat and ACE2/Ang 1-7 in DM 
4.5.1 ROS generation in DM 
Accumulating evidence suggests that the overproduction of ROS is one major factor in the 
onset and progression of diabetic complications as well as diabetes per se [281]. High glucose 
(25 mm D-glucose) induces the generation of ROS [124]. At the same time, Ang II, which is 
highly activated in DM, can potently stimulate ROS generation by heightened NADPH 
oxidase in mesangial cells and RPTCs [265, 282]. 
In addition of mitochondrial respiratory chain, another important source of ROS production is 
NADPH oxidase. The classic NADPH oxidase consists of membrane-bound subunits 
(gp91phox and p22phox) and cytosolic subunits (p47phox, p40phox, p67phox, and Rac).  
Griendling et al first reported NADPH oxidase regulation by Ang II in vascular smooth 
muscle cells [283]. Onozato et al confirmed in the kidney that NADPH oxidase activation is 
dependent on Ang II action on AT1 receptor and the blockade of AT1 receptor reduced 
p47phox expression and O2- production in the kidney [284]. Stimulation of AT1 receptor will 
lead to the activation of phospholipase D, protein kinase C (PKC), p38 mitogen activated 
protein kinase (MAPK) and c-Src tyrosine kinase stimulating the phosphorylation of p47phox. 
Once phosphorylated, p47phox translocates to the membrane where it will bind to the 
membrane component, cytochrome b558, through its two Src-homology 3 (SH3) domains. 
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Activation of c-Src also promotes the transactivation of epidermal growth factor receptor 
which leads to activation of phosphatidylinositol 3-kinase (PI3K) and Rac-1. Rac-1 then 
translocates to the membrane and keeps the enzyme complex activated [285]. 
Other homologues of gp91phox (Nox-2) in the phagocyte, including Nox-1, Nox-3, Nox-4, 
Nox-5, Duox-1 and Duox-2, have been described. At least three different NOX isoforms are 
expressed in the kidney cortex: NOX4, NOX2  and NOX1 [37]. NOX4 was originally 
identified as an NADPH oxidase homolog highly expressed in the kidney [40] and is the most 
abundant isoform. The predominant NOX4 localization within the kidney cortex is renal 
tubular cells, but at lower levels it is found in other cell types as well, including glomerular 
mesangial cells [37]. 
Ang II has also been shown to employ Nox4 as a mediator of injurious effects in tubular 
epithelial cells. Chronic Ang II treatment upregulates Nox4 expression and induces EMT in 
cultured renal epithelial cells through Nox4-dependent ROS production [286]. Furthermore, it 
was reported recently that Ang II upregulates Nox4 expression in the mitochondrial and 
membrane fractions and is required for Ang II-mediated mitochondrial and intracellular ROS 
production in cultured renal tubular cells [287]. 
In our studies, we found in Akita diabetic mice, NOX4 mRNA was increased, whereas NOX1 
and NOX2 mRNA expression did not change, compared to WT mice (Figure 2C, page 127). 
This is consistent with the in vitro findings that exposure of cultured renal proximal tubular 
epithelial cells to high glucose leads to the up-regulation of Nox4 protein expression, but has 
no effect on Nox2 or Nox1 expression [80]. Furthermore, You et al [81] investigated the role 
of NOX2 and Nox4 in diabetic kidney disease by using NOX2 knockout mice. Their study 
demonstrated that lack of Nox2 did not protect against diabetic kidney disease in T1D, despite 
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a reduction in macrophage infiltration. The lack of renoprotection may be due to upregulation 
of renal Nox4 [81]. We demonstrated that Ang II increases the expression of NOX4 both at 
mRNA and protein levels as shown by qRT-PCR, western blotting and immunostaining (Fig. 
2C-E, page 127).  
 
4.5.2 Ang 1-7 and ROS 
In our studies, Ang 1-7 administration normalized the expression of NOX4 in Akita mice, 
whereas A-779 reversed this change (Fig. 2A-E, page 127). These results are consistent with 
earlier observations. In the diabetic SHR kidney, Ang 1-7 decreased the elevated levels of 
renal NADPH oxidase (NOX) activity and attenuated the activation of NOX-4 gene 
expression [288]. In primary cultures of mouse mesangial cells, Moon et al. [289] showed Ang 
1–7 prevented the Ang II-induced expression of NOX subunits, including p47phox, p67phox, 
and NOX-4. 
 
4.5.3 Cat overexpression upregulates ACE2 
An important finding in our studies is that Cat overexpression could upregulate ACE2. But the 
underlying mechanism is still unknown. One possibility is that Cat interrupts the negative 
feedback of Ang II on the ACE2 expression. In our previous study, we observed that RAS 
blockade could normalize ACE2 expression, which is decreased in diabetic condition [250].  
Koka et al demonstrated that Ang II upregulates ACE and downregulates ACE2 expression in 
HK2 cells in vitro via the AT1R-ERK/p38 MAP kinase pathway [190]. Ang II can enhance 
the ROS generation by NADPH oxidase. The ROS, in turn, activates ERK1/2 and p38 MAPK 
in proximal tubular cells [290]. Therefore ROS mediates the negative feedback of Ang II on 
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4.5.4 Ang 1-7 upregulates ACE2 and Mas receptor 
 
Another important finding in our study is that Ang 1-7 could upregulate ACE2 and Mas 
receptor. Ang 1-7 mitigates ROS generation by reducing NOX4 expression. Thus, similar to 
Cat, Ang 1-7 could block the negative feedback of Ang II on the ACE2 expression, resulting 
in the upregulation of ACE2. Little is known on the regulation of Mas receptor. Lakshmanan 
et al [293] reported that Mas receptor and ACE2 were downregulated in STZ-diabetic mice 
and Telmisartan treatment could upregulate Mas receptor and ACE2. However, the 
mechanism whereby Ang 1-7 upregulates MasR still needs further investigation.  
 
4.6 Cat, ACE2/Ang 1-7 and kidney injury in diabetic mice 
4.6.1 Proteinuria in diabetic mice 
Microalbuminuria is an important clinical marker for the early detection of hypertension- or 
diabetes-induced nephropathy. Albuminuria/proteinuria results from defects in the glomerular 
filtration barrier, however, abnormalities in tubular albumin reabsorption may also contribute 
to proteinuria. The glomerular filtration barrier comprises a series of layers separating the 
blood side (glomerular capillary) from the urinary space. These include the innermost 
fenestrated endothelium, the middle GBM, and the outermost podocyte (also called the 
glomerular visceral epithelial cell), forming a size, charge, and conformational glomerular 
barrier. Low molecular weight proteins (mw<40 kDa) are essentially freely filtered, whereas, 
high molecular weight proteins (mw>100 kDa) are almost completely restricted [294]. 
Although the glomerular endothelium is highly fenestrated, it can still hinder protein 
permeability [295]. Widespread endothelial dysfunction is believed to result in proteinuria 
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[296]. GBM heparan sulfate proteoglycans (HSPGs) contributes to the charge selectivity of 
the glomerular capillary wall, since administration of a monoclonal anti-heparan sulfate 
antibody to rats induced massive proteinuria [297]. In vitro, decreased podocyte synthesis of 
the core protein agrin may be caused by both a high ambient glucose [254] and Ang II [253]. 
ACE inhibition prevents HSPG loss in diabetic rats, thus decreasing albuminuria [256]. 
Nephrin protein has been located to the slit diaphragm of glomerular podocytes, suggesting a 
role for nephrin in the renal ultrafilter barrier function. Mutations in the nephrin gene, NPHS1, 
leads to a severe congenital nephrotic syndrome [9]. Diabetic spontaneously hypertensive rats 
developed albuminuria and had a reduction in both gene and protein expression of nephrin 
when compared with control rats. Treatment of Irbesartan, an AT1 receptor antagonist, 
prevented the development of albuminuria and completely abrogated the down regulation of 
nephrin in diabetic rats [181]. 
Interestingly, an alternative model suggests interruption of the protein reabsorption process in 
the proximal tubule may cause nephrotic range proteinuria. Using fluorescently labelled 
albumin, together with the powerful technique of intravital 2-photon microscopy, Russo et al 
[298] showed that renal albumin filtration in non-proteinuric rats was ~50 times greater than 
previously measured and was followed by rapid endocytosis into RPTCs. In nephrotic rats, the 
rate of uptake of albumin by the proximal tubule is decreased. Thus, dysfunction of this 
retrieval pathway leads to albuminuria. In fact, 4–5 g of albumin are filtered at the normal 
glomerulus each day [299]. In diabetes, proximal tubular reuptake of protein may be impaired 
by high glucose [300], TGF-β [301], or Ang II [302].  
Cat overexpression upregulates ACE2 and thus counteracts the effect of Ang II. Chronic 
blockade of ACE2 with the enzyme inhibitor, MLN-4760, in control or diabetic mice 
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produced albuminuria [257]. In addition, Cat attenuates ROS, resulting in mitigating damage 
to proximal tubule. Taken together, Cat could reduce the degree of albuminuria.  
Ang 1-7 has been documented to decrease protein excretion. For instance, Benter et al [288]  
treated STZ-diabetic SHR with Ang 1–7 and found a significant reduction in urinary protein 
excretion compared with control diabetic rats. Ang 1-7 also induced a reduction in proteinuria, 
and systolic BP together with a restoration of creatinine clearance in Zucker diabetic fatty rats 
[273]. On the contrary, genetic deletion of the Ang 1–7 receptor Mas leads to glomerular 
hyperfiltration and microalbuminuria [164]. 
 
4.6.2 Tubulointerstitial injury in DN 
Although there is no question that there are changes seen in the glomerulus in patients with 
DN, it is also well known that tubulointerstitial changes are a prominent component of the 
disease [237]. The tubulointerstitium accounts for more than 90% of the kidney volume [303]. 
The progression of DN clearly is predicted by the extent of tubular atrophy and interstitial 
fibrosis [304]. The finding that cultured tubular cells respond to glucose suggests that these 
cells contribute directly to the pathological changes of DN rather than as a consequence of 
glomerular injury [305]. In T1D, tubulointerstitial disease has been seen to occur independent 
of glomerular disease [67]. Therefore Bonventre [237] proposed that the kidney tubule plays a 
critical role in the genesis of DN. Rather than the canonical view that the glomerular injury in 
DN is primary with the tubular injury secondary, he took the view that in fact the tubular 
injury is primary. Furthermore, the well-accepted data that disease progression is correlated 
best with the degree of tubulointerstitial disease is also consistent with a primary role for the 
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tubule, particularly the proximal tubule [237]. Therefore, our following studies focused on the 
tubular injury in DN. 
 
4.6.3 RAS, Cat and tubular hypertrophy 
Renal enlargement occurs in the early stage of DN. Since tubulointerstitial parenchyma 
accounts for 90% of the kidney volume, renal enlargement in diabetes predominantly reflects 
tubulointerstitial changes. In the STZ-induced diabetic rat, the first 7 days following the 
induction of experimental diabetes are accompanied by a 37% increase in proximal tubular 
length, a doubling of luminal diameter and wall volume, and an increase in cell height [36], 
reflecting both hypertrophy and hyperplasia [37]. However, the growth pattern switches early 
from hyperplasia to hypertrophy growth at around day 4 in the model of STZ diabetes [306]. 
This renal enlargement is associated with an increase in GFR.  
Akita mice exhibited elevated kidney-to-body weight ratio at the end of the experiment 
compared with non-Akita WT controls (Table 2-1, page 88). In agreement with this, a 
significantly enlarged tubular luminal area and increased glomerular tuft and RPTC volume 
were observed in Akita mice compared with non-Akita WT (Table 2-1, page 88). Cat 
overexpression markedly attenuated these ratios, partially reduced tubular luminal area and 
glomerular tuft volume and completely normalized RPTC volume in Akita Cat-Tg mice. 
The mechanism by which tubular hypertrophy occurs in DM remains to be elucidated. Ang II 
and TGF-β1 might be important mediators.  Ang II could increase TGF- β1 gene expression 
via AT1R in RPTCs. Zhang et al [307] have observed this effect in vitro where Ang II 
stimulation of immortalized rat proximal tubular cells induces cell hypertrophy. TGF-β can 
induce a G1 phase cell cycle arrest by induction of the cyclin-dependent kinase (CDK) 
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inhibitor p27KIP1 (p27) [308], which can also be induced in diabetes by PKC [309]. Diabetes 
also increases the renal expression of the CDK p21 and loss of p21 increases tubular cell 
proliferation [310]. The role of ROS is indicated by the fact that the antioxidants N-
acetylcysteine and taurine attenuated high-glucose-induced activation of the JAK/STAT 
signalling pathways, p21 and p27 expression, and hypertrophic growth in renal tubular 
epithelial cells [311]. Similar to these antioxidants, Cat could effectively attenuate ROS, 
leading to mitigating tubular hypertrophy. 
 
4.6.4 Cat, RAS and tubulointerstitial fibrosis 
Although the glomerulus has been the focus of intense investigation in diabetes, 
tubulointerstitial injury, characterized by tubulointerstitial fibrosis and tubular atrophy, is also 
a major feature of diabetic nephropathy and an important predicator of renal dysfunction 
[238]. The renal tubule in diabetes is subject to pathogenetic influences as a consequence of its 
position in the nephron and its reabsorptive function.  
To assess tubulointerstitial fibrosis, we performed Masson’s trichrome staining and 
immunostaining for collagen type IV. Kidneys from Akita mice (Fig. 4, Bc and Dc, page 94) 
exhibited significantly higher expression of collagenous components and collagen type IV 
relative to non-Akita WT (Fig. 4, Ba and Da, page 94). Cat overexpression markedly reduced 
tubulointerstitial fibrosis (Fig. 4, Bd and Dd) as demonstrated by quantitative analysis of 
Masson’s trichrome staining (Fig. 4C, page 94) and immunostaining for collagen IV (Fig. 4F, 
page 94). Quantitation of collagen IV (Fig. 4H, page 94) expression further confirmed these 
findings. Collectively, these data indicate that Cat overexpression effectively prevents 
tubulointerstitial fibrosis in Akita Cat-Tg mice. 
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The precise mechanism by which oxidative stress leads to interstitial fibrosis in Akita mice 
remains unclear. One possibility is that augmented Ang II expression via ROS generation 
stimulates TGF-β1 and subsequently enhances the expression of extracellular matrix proteins. 
TGF-β1 is known to have powerful fibrogenic actions resulting from both stimulation of 
matrix synthesis and inhibition of matrix degradation [312]. Ang II stimulates mesangial 
matrix synthesis, an effect mediated by TGF-β [178]. The Ang II competitive inhibitor 
saralasin prevented the effects of Ang II [178]. Similar effects of Ang II on TGF- β synthesis 
also occur in proximal tubule cells [313]. Cat overexpression significantly attenuated the ROS 
generation and normalized ACE2 and ACE expression, resulting in the decrease of Ang II. 
Thus, Cat overexpression could decrease TGF-β expression (Fig. 4C, 4E, 4G and 4I, page 94), 
subsequently ameliorating fibrosis. Similarly, Ang 1-7 could attenuate ROS generation and 
upregulate ACE2 expression, reducing tubular fibrosis. 
Recently Mori et al [314] studied the mechanism of Ang 1-7-induced beneficial effects on DN 
in db/db mouse. The genetic background of the mice is C57BL/6J and therefore no 
hypertension was observed. These effects were associated with reduction of oxidative stress, 
fibrosis, inflammation and lipotoxicity. Ang 1-7 attenuated renal ROS production via reduced 
NADPH oxidase activity, as we observed on our experiment. In T2D, insulin resistance and 
renal lipid accumulation are involved in the pathogenesis of diabetic nephropathy [315]. Ang 
1-7 can ameliorate lipid metabolism related pathway, such as sirtuin- FOXO1- ATGL (adipose 
triglyceride lipase), as well as inflammation in perirenal adipose tissue, which plays an 
important role in the development of insulin resistance [314].  
In our experiment, we found that Ang 1-7 could normalize the expression of ACE2 in 
proximal tubule. An explanation for this is that Ang 1-7 regulates the shedding of ACE2.  As 
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showed in Figure 3-6 (page 135), TACE expression was increased in Akita mice. 
Administration of Ang 1-7 could attenuate the TACE expression and increase intrarenal ACE2, 
leading to the improvement of hypertension and DN. 
 
4.6.5 Cat, Ang 1-7 and tubular apoptosis 
 
Atubular glomeruli, glomeruli that not connected to proximal tubules, have been reported in 
both type 1 and type 2 diabetes [316, 317]. From T1D patients,  atubular glomeruli may occur 
in 8–17% of nephrons [317]. Tubular atrophy results in the glomerulus losing its connection to 
a functional tubule [237]. Furthermore, tubular atrophy appears to be a better predictor of renal 
disease progression than glomerular pathology because of its close association with loss of 
renal function [318]. 
The mechanisms underlying tubular atrophy remain unclear. One possible mechanism is 
apoptosis. In our studies, we detected higher number of apoptotic RPTCs in Akita mice. 
Overexpression of Cat in the kidney could mitigate the apoptosis in RPTC. The mechanism(s) 
by which RPTC apoptosis increases with DM remains undefined. One possibility is oxidative 
stress, directly from hyperglycemia or from activation of NADPH oxidase by Ang II. 
Increased ROS generation activates p38 MAPK signalling, in turn stimulating p53 
phosphorylation [319]. Phosphorylated p53 then translocates to the nucleus and induces the 
expression of Bax gene [320]. Bax translocates to the mitochondria and competes with the 
anti-apoptotic proteins Bcl-2 and Bcl-xL, leading to mitochondrial dysfunction, mitochondrial 
outer membrane permeabilization and ultimately, caspase-3 activation. Our data on increased 
Bax and caspase-3 expression, together with decreased Bcl-xL expression in RPTs of diabetic 
mice, lend support to this notion. Furthermore, enhanced intrarenal RAS activation in the DM 
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stimulates Bax mRNA and protein expression per se [182]. Another explanation is role of 
TGF-β, which was reported to promote apoptosis after renal injury in both in vivo and in vitro 
models [321, 322]. Cat overexpression could effectively attenuate ROS production and 
therefore block the above signal pathways. Furthermore, Cat overexpression could upregulate 
ACE2 expression, resulting in attenuated Ang II. Taken together, Cat overexpression leads to 
the decreased Bax/Bcl-xL ratio and finally attenuated caspase-3 activation. 
 
4.7 Comparison between Ang 1-7 and RAS blocker 
Interestingly, Zhang et al compared the effect of Ang 1-7 with AT1R antagonist on the DN. 
They reported that Ang 1–7 ameliorated STZ-induced diabetic renal injury in a dose-
dependent manner, and the renoprotective effect of large-dose Ang 1–7 treatment was superior 
to valsartan treatment [323]. The combined treatment of Ang 1–7 and valsartan had no 
additive effects. The possible mechanisms of Ang 1–7-mediated effects involved reduced 
renal oxidative stress regulated by NOXs and PKCs, and inhibited TGF-β1/Smad3 and VEGF 
signalling [323]. Another study used a recombinant adenoviral-mediated ACE2 gene transfer 
(Ad-ACE2) and/or ACEi in a rat model of DN to compare the effects of the combined 
therapies (Ad-ACE2 + ACEi) and isolated therapy (Ad-ACE2 or ACEi) on glomerular 
morphology and function and to explore the signaling pathways mediating these therapeutic 
effects [195]. The study demonstrated that Ad-ACE2 and ACEI had similar effects, whereas 
combination of Ad-ACE2 and ACEi offered no additional benefits. To date, no comparison 
has been performed between the effect of Ang 1-7 and that of ACEi. However, several 
guidelines suggest that ACEi and ARB are equivalent on the DN [324], thus Ang 1-7 
treatment might be superior to ACEi treatment. 
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4.8 ACE2 and non-diabetic kidney disease 
Inhibition of the RAS by ACEi and/or ARB can reduce albuminuria/proteinuria independent 
of the baseline degree of albuminuria/proteinuria and underlying disease and has become 
standard practice for delaying the progression of kidney disease both in patients with diabetic 
nephropathy and in non-diabetic albuminuric patients [325, 326]. ACE2 seems to have the 
same effect as ACEi or ARB; however, much less investigations on ACE2 have been 
performed in non-diabetic kidney disease than in DN. In patients with IgA nephropathy, 
increased glomerular ACE expression and decreased ACE2 expression were observed in both 
the tubulointerstitium and glomeruli, as in DN [327]. Roberts et al. [328] showed that among 
patients with CKD plasma ACE2 activity is lower in those undergoing hemodialysis for ESRD 
when compared with predialysis patients with CKD or renal transplant patients. These 
findings suggest that decreased ACE2 activity may be involved in the pathogenesis of kidney 
disease [329].  Zhang et al demonstrated that a 5-day infusion of Ang 1–7 reduced proteinuria 
and improved glomerulosclerosis experimental glomerulonephritis [330]. Treatment with the 
Mas receptor agonist AVE 0991 improved renal function parameters, reduced proteinuria and 
attenuated histological changes in a murine model of adriamycin-induced nephropathy [331]. 
Dilauro et al. demonstrated that kidney ACE2 is downregulated in early CKD in the 5/6 
nephrectomy in FVB mice. Moreover, inhibition of ACE2 increases kidney Ang II levels and 
albuminuria via an AT1 receptor-dependent mechanism. Their data also indicated that 
administration of Ang 1–7 to 5/6 nephrectomy mice normalizes kidney ACE2 expression and 
levels of Ang II in kidney and plasma, yet does not affect BP, albuminuria, or FITC-inulin 
clearance [332]. Therefore endogenous ACE2 is renoprotective in CKD; however, the 
beneficial effect of ACE2 therapy on the non-diabetic CKD still need further study. 
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4.9 Limitations of the present study 
We used a Tg mouse model overexpressing rCat in their RPTCs to study the role of ACE2 in 
the development of hypertension and DN. Although we demonstrated that the beneficial effect 
of Cat on the hypertension and DN was because of up-regulation of ACE2, the study is not as 
direct as the one using ACE2 Tg or ACE2 knockout mice. In fact, we have attempted to create 
Tg mice overexpressing ACE2 in RPTCs.  We placed human ACE2 cDNA fuse with a HA tag 
at the 5’ terminal into pKAP2. Southern blot analysis revealed the presence of the transgene in 
heterozygote and homozygote animals. RT-PCR also showed Tg specifically expressed in 
kidney not in other tissue. Unfortunately, however, we could not detect more ACE2 protein 
expression in the RPTCs by both western blot and IHC, compared to WT. Neither did we 
detect increased ACE2 activity in Tg mice. Why the Tg did not express in the protein level is 
still unknown. 
Another limitation of the present study is the method we used to administer Ang 1-7. 
Previously we implanted mini-pump with Ang 1-7 into the back of Akita mice. This method 
could provide continuous drug delivery and were supposed to more conform to 
pharmacological rule. However, the experiment failed because all the implanted mini-pump 
came out. Lack of subcutaneous fat and dehydration of skin in diabetic condition prevent the 
cut from healing. In the end, we employed one-shot subcutaneous injection to treat the animal 
every day.  
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apoptotic genes, pro-fibrogenic genes. These findings will confirm whether Ang 1-7 alone 
contributes to the renal protective role of ACE2. 
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